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TARGETED DUAL FUNCTIONAL NANOPARTICLES FOR THE TREATMENT OF 
CANCER AND LIVER FIBROSIS 
Mohammed Ghazwani, PhD 
University of Pittsburgh, 2015 
For decades, a large number of therapeutics have been discovered and developed with high 
potential for curing various diseases, many of which have been clinically used for years. 
However, some treatments are greatly limited due to their side effects, which arise from their 
inability to differentiate between normal and diseased cells. The aim of this dissertation work is 
to develop nanomaterial-based dual function drug delivery systems to improve overall 
therapeutic outcomes for the treatment of cancer and liver fibrosis.  
The first part of this work focused on the development of FTS-based solid lipid 
nanoparticles (SLNs) for cancer-targeted delivery of paclitaxel (PTX). Novel SLNs were 
successfully developed which are capable of solubilizing PTX while simultaneously avoiding 
unwanted side effects of the clinically used PTX formulation (Taxol). The data from this study 
demonstrated that the PTX-SLNs system has a significantly improved profile in terms of 
controlled release kinetics and stability compared to Taxol. Additionally, PTX-SLNs have shown 
enhanced anticancer activity in vivo. 
The second part focused on improved delivery of the herbal agent thymoquinone (TQ) to 
hepatic stellate cells (HSCs) for the treatment of liver fibrosis. Firstly, a study was conducted on 
the biological effects of TQ on HSCs, which represent the major liver cell type involved in the 
massive production of extra cellular matrix (ECM) in liver fibrosis. The results revealed that TQ 
exerts hepatoprotective and anti-fibrotic effects via direct inhibition of the fibrogenic activities of 
HSCs, which suggests that TQ holds great potential as a new drug candidate for treatment of 
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liver fibrosis. Secondly, an examination was conducted on the potential of a novel dual 
functional micellar system PEG5k-Fmoc-FTS2 to deliver TQ into activated HSCs in vitro. TQ-
micelles have shown high tolerability in activated HSCs with more efficient anti-fibrotic activity 
compared to free TQ.    
Collectively, this work suggests that an FTS-based SLNs system represents a promising 
nanocarrier for cancer-targeted delivery which could enhance the therapeutic efficiency of 
anticancer agents. In addition, TQ holds a great a potential as new therapy for the treatment of 
liver fibrosis, and formulating TQ into the PEG5k-Fmoc-FTS2 micelles system could further 
enhance overall anti-fibrotic activity.  
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1. TARGETED DELIVERY OF ANTICANCER AGENTS  
1.1. INTRODUCTION 
1.1.1. Current status of cancer treatment 
Cancer is the most prominent disease of the 21st century, and represents an increasingly difficult 
challenge over time. Although science and technology have progressed remarkably over the last 
decades, they remain incapable of providing a cure for cancer. Cancer is not a single disease, but 
rather a group of diseases. However, they all begin with abnormal cells that grow uncontrollably.  
According to the International Agency for Research on Cancer (IARC) (2015b) , the 
number of estimated cancer deaths in 2012 was 8.2 million worldwide. This accounts for 58% of 
the total estimated new cases of the same year. The 2015 United States cancer statistics, revealed 
by the National Cancer Institute, estimate that 1,658,370 cases are expected to be registered 
during this year, of which 589,430 are estimated deaths from all cancer types (Siegel et al., 
2015). The 5-year survival rate between 2005 and 2011 was 66.5%, which represents an 
improvement when compared to 49% between 1975 and 1977 (2015a). This is likely due to an 
improvement in treatment and the constant evolution of tools which assist in the detection of 
certain types of cancer at their early stages.  
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Several factors contribute to the incidence of cancer. Tobacco use is the leading cause, 
accounting for 20-30% of all risk factors. Both active and secondhand smokers are at high risk of 
developing cancer, because chemicals in tobacco can cause damage to DNA. Another leading 
cause is linked to diet and obesity, which represents 30% (Doll and Peto, 1981; Anand et al., 
2008). In fact, diet is responsible for approximately 70% of colorectal cancer cases. This factor is 
difficult to control, since many carcinogenic materials such as nitrate, pesticide, and dioxin are 
used in the food industry (Abnet, 2007; Hogg, 2007). Infectious diseases play a major role in 
cancer occurrence. Up to 20% of cancer cases are related to infections, of which viral infection 
being the dominant type. For example, nearly all cases of cervical cancer are caused by human 
papillomavirus in Western developed countries (Pisani et al., 1997; Parkin, 2006). Although 
cancer is caused by molecular genetic mutations, these mutations are the result of exposure and 
interaction with external environmental factors. Only approximately 5-10% of cancers are linked 
to genetic defects inherited from parents. The remaining percentage includes environmental 
pollution, alcohol, family history, radiation, and other factors (Loeb and Loeb, 2000; Mucci et 
al., 2001; Hahn and Weinberg, 2002). 
Currently, the most common treatment options include surgery, radiotherapy, 
chemotherapy, immunotherapy, and targeted therapy. Additionally, a combinational therapy 
including some of the aforementioned treatments can be considered depending on the type and 
stage of the disease. However, many limitations and downsides exist for each treatment option. 
Although surgery is the only treatment option that may provide a realistic chance for curing 
cancer, it is only applicable when the cancer is localized and hasn’t spread to other tissues; and 
also if tumor removal will not damage any vital organs. Typically, surgery will be the first option 
if cancer is detected early. Radiation treatment is characterized by its specific targeting to the 
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tumor area using special radiation such as x-rays and gamma rays. However, radiation itself may 
cause skin irritation, damage to nearby tissue, and patients may suffer from fatigue. Patients 
undergoing chemotherapy normally suffer from side effects caused by anticancer drugs, 
including hair loss, nausea, vomiting, and loss of appetite. Despite the high efficacy of these 
chemotherapeutic agents, they lack the specificity in tumor targeting. Consequently, the agents 
spread into healthy tissues and kill normal cells simultaneously (Sutradhar and Amin, 2014). 
Therefore, safer alternatives which guarantee antitumor efficacy without the accompanying 
harmful side effects are highly in demand.  
A variety of techniques have been investigated over the past few decades which are 
sought to discover an optimal remedy for cancer treatments; the most promising technique 
among them is nanotechnology. The potential therapeutic benefits of nanotechnology are not 
only limited to cancer treatment, but also in the detection and prevention of the disease. The 
unique functional properties of nanotechnology, such as the possibility of delivering drugs 
specifically into tumor cells without harming normal cells, and the potential for overcoming drug 
resistance and side effects have made it a very attractive field in cancer research. In fact, several 
nanocarriers such as Doxil, Abraxane and Myocet have successfully made it into the clinic for 
their significant advantages over conventional treatments (Pillai, 2014).  
 
1.1.2. Nanotechnology and its application in cancer treatment 
Nanotechnology is a multidisciplinary field which represents a combination of many basic 
sciences, such as chemistry, physics, engineering, and biology. Nanotechnology can be defined 
as materials of nanoscale size between 1-100 nm which possess the ability to deliver drugs or 
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imaging agents for the purpose of treatment or diagnosis (Peppas, 2004; Ferrari, 2005). A 
Nanoparticle system is typically composed of a core, corona, payload, and targeting ligand 
(Figure 1).   
Figure 1. Nanoparticles platform structure, including core, payload, corona, targeting ligand. 
Adapted from (Alexis et al., 2010) 
The early discovery of nanotechnology was first described in 1960s by British 
haematologist Alec Bangham. When Bangham and his colleague R.W. Horne were testing a new 
electron microscope at the Babraham Institute, in Cambridge, UK  using dry phospholipids 
dispersed in water, they noticed that this material was able to form closed-membrane  spherical 
vesicles similar to cell membrane which was known later as liposomes (Bangham et al., 1965). 
Following this discovery, remarkable progress has been achieved, enabling improved design and 
fabrication of nanosystems. In 1976, Langer and Folkman introduced the first controlled release 
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system for macromolecule delivery (Langer and Folkman, 1976), followed by the first 
application of antibody-decorated liposomes for targeted therapy in 1980 (Heath et al., 1980; 
Leserman et al., 1980). When PEGylated liposomes were introduced in 1990, they greatly 
improved nanoparticle stability and prolonged their circulation time in blood, representing 
another major breakthrough (Klibanov et al., 1990; Gref et al., 1994). This opened new scopes 
for the development of new strategies to re-evaluate existing effective nanosystems which were 
abandoned for their short stability in blood.  
Many obstacles for conventional chemotherapy have hindered its clinical applications, 
including poor water solubility, non-specific targeting, and multidrug resistance (Dong and 
Mumper, 2010; Chidambaram et al., 2011; Sutradhar and Amin, 2014). Most anticancer agents 
are hydrophobic in nature, which make their oral administration very difficult, and additionally 
expose them to GI metabolism, leading to degradation or modification to inactive or toxic 
metabolites. Therefore, the intravenous (i.v.) route represents a better option that increases the 
bioavailability and benefit of most drugs (Hande et al., 1999). However, hydrophobic drugs must 
be dissolved in an aqueous solution, which creates additional challenges in suitability for i.v. 
administration. Increasing drug hydrophilicity by chemical modification of parent compounds is 
possible, but the probability of a loss in drug activity becomes high (Savjani et al., 2012). 
Moreover, the use of adjuvant solvents to solve this issue, such as Taxol (Paclitaxel dissolved in 
Cremophore EL and dehydrated ethanol) could likely cause unwanted side effects such as 
hypersensitivity reactions (Gelderblom et al., 2001b). Moreover, conventional chemotherapy is 
distributed throughout the entire body following i.v. administration, and non-specifically targets 
normal cells, which causes severe side effects. Furthermore, substantial amount of drug are 
quickly cleared by the reticuloendothelial system (RES) (Alexis et al., 2008; Li and Huang, 
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2010; Wang et al., 2012), leading to insufficient drug levels becoming present in the tumor, 
resulting in minimal antitumor activity. Such treatments could even worsen disease condition by 
triggering tumor cell resistance to anticancer drugs. Tumor cells have the capability to respond to 
treatment by launching defensive mechanisms via the overexpression of P-glycoprotein (P-gp) 
efflux membrane transporter, resulting in multidrug resistance (MDR) and the production of 
more aggressive tumor forms (Gottesman, 1993; Dong and Mumper, 2010). Therefore, 
solubilizing hydrophobic drugs in a carrier that selectively targets tumors and is capable of 
escaping clearance by RES would greatly maximize therapeutic benefits while avoiding the 
potential side effects of conventional therapy.  
Nanotechnology offers potentially promising solutions for all of the aforementioned 
challenges. The physiochemical properties and small particles sizes that characterize 
nanoparticles (NPs) enable them to improve drug solubility and efficiently decrease their 
interaction with blood proteins, allowing them to circulate longer in blood stream. Moreover, 
these properties play a role in the ability to specifically target tumor sites and increase drug 
bioavailability by taking advantage of the leaky vasculatures and poor lymphatic drainage in 
tumor tissues. This phenomenon is known as the enhanced permeability and retention (EPR) 
effect (Maeda et al., 2000; Duan et al., 2010a) (Figure 2). 
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Figure 2. Enhanced permeability and retention (EPR) effect. 
Adapted from (Alexis et al., 2010) 
A variety of nanocarriers have been developed for treatment and diagnostic purposes. 
Among these nanocarriers, liposomes are the most extensively studied platform. In fact, several 
formulations have made it to clinical applications for the treatment of Kaposi's sarcoma, ovarian 
and breast cancer, with many applications currently in clinical trials (Fan and Zhang, 2013). 
Liposomes are composed of phospholipids that, in aqueous solution, form spherical vesicles with 
a hydrophilic core encapsulated by at least one lipid bilayer. Liposomes have the ability to carry 
both hydrophilic and lipophilic agents. Doxil is one example of a liposomal formulation that is 
coated with polyethylene glycol (PEG) to deliver doxorubicin for cancer treatment (Senior, 
1986; Torchilin, 2005; Immordino et al., 2006).   
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Another example, polymeric NPs are composed of biodegradable polymers that self-
assemble in an aqueous environment, thereby encapsulating hydrophobic agents. Genexol-PM is 
a poly (D,L-lactic-co-glycolic acid)  (PLGA) NP for paclitaxel delivery that has been approved 
in South Korea and currently under phase III-IV clinical trials in the United States for the 
patients with recurrent breast cancer (Soppimath et al., 2001; Kim et al., 2007; Ledet and 
Mandal, 2012; Wang et al., 2012).  
The aforementioned platforms are categorized as passive targeting NPs, which essentially 
rely on the physicochemical properties of NPs and the EPR effect in the tumor area to reach their 
target. Another technique is active targeting, where the NP’s surface can be fabricated with a 
targeting moiety such as proteins, antibodies, or other ligands that can selectively interact with 
the antigens or cell receptors overexpressed in tumor cells. Currently, several NPs that are based 
on passive targeting have been approved for clinical use; however, active targeting NPs are still 
in clinical trials (Schäfer-Korting, 2010).  
1.1.2.1. PEG-decorated nanoparticles  
Although nanotechnology has improved the therapeutic outcomes of conventional chemotherapy, 
one major barrier against the use of NPs is their attack by opsonins in the bloodstream, and the 
subsequent removal by RES within short time after i.v. injection. The processes known as 
opsonization and phagocytosis are the first line defense against any foreign bodies or particles 
entering blood circulation. In order for phagocytes to recognize foreign materials, opsonin 
proteins must guide them by binding to a particle’s surface so it may be identified as an invader. 
Then, phagocytic cells take up the foreign particles, and destroy them. Opsonins represent any 
blood materials which are involved in the process of phagocytic recognition; these include 
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albumin, immunoglobulins, fibronectin, and laminin, among others (Moghimi and Szebeni, 
2003; Owens and Peppas, 2006).  
 One key step in escaping opsonization involves preventing recognition by phagocytes. 
One of the most successful methods used to achieve this goal is the covering of NPs’ surfaces 
using a hydrophilic polymer which acts as shield against opsonins and eventually bypasses 
phagocytic recognition (Klibanov et al., 1990; Li and Huang, 2010). Among these polymers, 
PEG, an FDA-approved hydrophilic polymer, holds the most promise based on its flexibility and 
excellent safety profile. The development of NPs decorated by PEG molecules (PEGylated-NPs) 
not only reduces exposure to RES uptake, but also extends the half-lives when compared to non-
PEGylated NPs. Early attempts to use PEG in the field of drug delivery dates back to a 1977 
study, where methoxy-PEGs (mPEGs) was conjugated to bovine serum albumin and liver 
catalase (Abuchowski et al., 1977). Additionally, modification of microspheres’ surfaces with 
surface-localized human serum albumin with polyethylene glycol resulted in a two-fold increase 
in the half-life of the carrier (Arturson et al., 1983). Ten years later, Li and coworker reported 
that latex particles coated with PEG 5000 kDa remained in rat blood for 13 h, while uncoated 
particles only lasted for 20 min (Tan et al., 1993).   Klibanov and Huang discovered that the 
fabrication of liposome NPs with dioleoyl N-(monomethoxy polyethyleneglycol succinyl) 
phosphotidylethanolamine (PEG-PE) increased their t1/2 10-fold without significant leakage of 
liposome content (Klibanov et al., 1990). This research in PEG applications for drug delivery 
development led to the first FDA-approved PEGylated NPs in the mid-1990s: Doxil® (liposomal 
delivery vehicle for doxorubicin) and oncospar (PEG-l-asparaginase). Doxil formulations have 
increased doxorubicin bioavailability 90-fold when compared to free drug administration.     
 10 
1.1.2.2. Dual functional carriers  
The vast majority of NPs being developed for optimal drug delivery are usually based on inert 
carriers. These carriers are biologically inactive regardless of their advantageous properties in 
terms of drug solubility and stability. However, these carries add to the cost and raises potential 
safety concerns. The recruitment of bioactive compounds which can functionally replace the 
carrier’s inert part and offer potential therapeutic benefits is being investigated as an effective 
approach for the design of dual functional NPs. Our laboratory has been investigating a number 
of therapeutic agents for this purpose. Indeed, in vitro and in vivo data from several promising 
PEG-conjugate micellar systems have demonstrated significantly improved antitumor activity. 
These conjugates improved the overall anticancer effect via synergizing with delivered 
anticancer agents such as paclitaxel and doxorubicin, while enhancing formulation’s stability and 
drug loading capacity (Huang et al., 2012; Lu et al., 2013; Zhang et al., 2013b; Lu et al., 2014b; 
Zhang et al., 2014d).  
For instance, a dual functional carrier based on PEG-derivatized embelin was developed 
as a novel micellar system for the delivery of paclitaxel. Embelin is a natural compound 
extracted from Embelia ribes BURM. Embelin has been studied for a variety of therapeutic 
activities, including antidiabetic, anti-inflammatory, and hepatoprotective activities. Moreover, 
several studies have highlighted its antitumor activities in many types of cancer. Embelin induces 
apoptosis through the inhibition of X-linked inhibitor of apoptosis protein (XIAP), which is 
overexpressed in tumor cells, especially in drug-resistant cells, which makes embelin capable of 
reversing multidrug resistance. Moreover, embelin exhibits significantly less toxicity in normal 
cells due to the low impact of XIAP in normal cells (Chitra et al., 1994; Danquah et al., 2009). 
Apart from its therapeutic benefits, the poor water solubility of embelin makes it an excellent 
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candidate as hydrophobic carrier component that can be conjugated to a PEG hydrophilic 
polymer to form dual functional micellar systems. In vitro cytotoxicity analysis indicated that 
PEG-embelin micelles not only maintained a similar antitumor activity to free embelin, but also 
exhibited a synergistic effect with loaded PTX in human breast and prostate cancer lines. Also, 
in vivo antitumor study in murine models of breast and prostate cancers exhibited significantly 
improved tumor growth inhibition when compared to a Taxol formulation (Huang et al., 2012).  
Another dual functional micellar system reported by our group is based on PEG-
farnesylthiosalicylic acid (FTS) conjugate. (Zhang et al., 2013b). FTS is a synthetic, non-toxic, 
and potent Ras inhibitor. Ras mutation occurs in about one-third of cancers, with a highest 
incidence (nearly 90%) in pancreatic cancer. Mutation of Ras genes leads to permanent 
activation of the Ras pathway, which subsequently promotes uncontrolled cell growth. One of 
the major mechanisms by which FTS exerts its antitumor activity is binding to the anchorage 
domain of Ras protein in the plasma membrane, resulting in Ras protein dislodgement followed 
by the degradation and inhibition of effector signaling (Marciano et al., 1995; Haklai et al., 
1998a). More importantly, FTS (hydrophobic in nature, see Figure 3) conjugated with PEG 
improved water solubility and self-assembled to very small nanomicellar particles (20-30 nm) 
suitable for hydrophobic anticancer agents such as PTX. An in vitro release study has indicated 
slower release kinetics in FTS-micelles when compared to Taxol. Also, PEG-FTS micelles 
exhibited comparable activity to free FTS, as evidenced by similar cytotoxicity in several cancer 
cell lines as well as Ras protein downregulation analyzed by Western blot. Moreover, PTX-
loaded PEG-FTS micelles have significantly inhibited tumor growth in a syngeneic murine 
breast cancer model when compared to Taxol formulation, suggesting improved accumulation of 
 12 
micelle particles at tumor sites and possible synergy between the carrier and PTX (Zhang et al., 
2013b).  
  
S
COOH  
                                                            Figure 3. Chemical structure of FTS 
 
1.1.2.3. Solid nanoparticles in cancer targeted therapy 
Solid lipid nanoparticles (SLNs) are colloidal systems with a submicron size range. As the name 
implies, they consist of a hydrophobic lipid core present in a solid state at room and body 
temperatures. The solid core is surrounded by a monolayer of phospholipid coating, forming 
spherical particles. The active drug is dissolved or dispersed within the solid matrix (Wissing et 
al., 2004).  
The idea behind SLN development dates back to the early 1990s, when scientists were 
searching for alternatives to overcome the limitations of NPs through liposome and polymeric 
NPs. Despite the increased efficacy and reduced side effects of incorporated drugs that liposomes 
offer, major drawbacks remain, including limited physical stability, leakage of loaded drugs, and 
large scaling hurdles (Gregoriadis, 1988). Similarly, polymeric NPs provide enhanced tumor 
targeting and controlled release of loaded drugs, however, there are growing concerns regarding 
polymer cytotoxicity following their uptake by cells, as well as their scale up difficulty  (Fu et 
al., 2000). SLNs were developed as an alternative carrier for conventional NPs. SLNs combine 
the advantages and avoid some of the shortcomings of existing traditional carriers (e.g. improved 
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stability profile, protection of loaded drug from degradation, improved controlled release, 
enhanced bioavailability, and excellent biocompatibility). Moreover, SLNs are considered less 
costly in large-scale production when compared to liposomes (Wissing et al., 2004). SLNs also 
possess a broad range of applications in many diseases, including cancer. However, SLNs also 
carry some potential disadvantages, including limited drug loading capacity, unpredictable 
gelation tendency, and particle growth. Researchers have designed SLNs formulations suitable 
for different routes of administration such as parenteral, oral, dermal, ocular, pulmonary, and 
rectal routes. Due to the physicochemical properties of SLNs, they have the potential to carry 
both hydrophilic and hydrophobic drugs. Also, based on their material composition, SLNs are 
generally recognized as safe (GRAS) (Schwarz, 1999; Muller et al., 2000a; Wissing et al., 2004). 
A variety of biodegradable lipids can be used to prepare SLNs (e.g. triglycerides and lipid acids); 
in addition, SLNs work compatibly with many types of surfactants, such as lecithin, Tween 80, 
and Poloxamer 188. With all of these features, SLNs represent a promising delivery platform for 
cancer chemotherapy.  
Several studies have reported SLNs’ ability to protect anticancer drugs from degradation. 
Researchers have tested all-trans retinoic acid (Rachagani et al.) (Rachagani et al.) stability in 
SLN formulation (Lim et al., 2004). ATRA is known for its light, heat, and oxidant sensitivity, 
which upon degradation may yield less active compounds, such as all-trans-4-oxo (Brisaert et al., 
2000). Following three months of storing ATRA-loaded SLNs at 4 °C, researchers discovered 
that over 90% of the ATRA remained active, compared to only 50% of the control (ATRA 
dissolved in a methanol solution) whithin only one month. A numbers of studies have 
investigated SLNs’ ability to enhance the treatment outcomes of anticancer agents. Naguib et al. 
have shown an improved antitumor effect of Docetaxel-encapsulated SLN formulation (DCX-
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SLN), which is composed of the high melting point lipid trimyristin, compared to free drug being 
dissolved in a Tween 80/ethanol solution both in vitro and in vivo (Naguib et al., 2014a). DCX-
SLNs’ average size was 180 nm. Also, they observed significant accumulation of DCX-SLNs in 
tumors 12 h after injection. Simultaneously, overall lower uptake by vital organs, especially the 
liver, has been reported. This study suggests that the SLN system may provide a favorable safety 
profile for DCX delivery. Another study adopted an active targeting technique, similar to 
liposomes, in SLNs formulation (Stevens et al., 2004). The researchers developed an SLN 
formulation equipped with a folate receptor targeting moiety (FR-SLNs) for the delivery of 
paclitaxel prodrug (paclitaxel-2′-carbonylcholesterol). Folate receptors are highly expressed in 
many types of cancer. FR-SLNs exhibited much higher cell uptake with a greater cytotoxic effect 
in vitro compared to non-targeted SLNs. Similarly, improved tumor growth inhibition was 
demonstrated for FR-SLNs compared to both non-targeted and paclitaxel in Cremophore El 
formulation in a FR (+) M109 tumor model. 
SLNs also have been investigated for their potential to deliver genetic materials in cancer 
treatment. Jin et al. developed a cationic SLNs system for the delivery of PEGylated c-Met 
siRNA into brain tumors in a mouse model (Jin et al., 2011). The siRNA-PEG/SLNs complex 
was able to cross the blood brain barrier (BBB) and efficiently downregulate the c-Met gene 
without the association of systemic toxicity. Although the history of SLNs is relatively short 
compared to that of many NPs, significant progress toward SLNs development has been 
achieved. However, no clinical SLNs formulations are available on the market. Considering the 
features which SLNs may offer to overcome chemotherapy barriers, SLN formulation represents 
a flexible and promising delivery system which has attracted increasing attention in recent years. 
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Increased effort should be invested in this formulation to provide a safer and more efficient 
clinical alternative in the future.  
These findings suggest that SLNs can be utilized to improve the targeting ability of NPs 
and provide a promising tool for the development of targeted therapy.  
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1.2. NOVEL FARNESYLTHIOSALICYLATE (FTS)-BASED SOLID LIPID 
NANOPARTICLES FOR IMPROVED TARGETED DELIVERY OF 
PACLITAXEL 
 
1.2.1. Abstract 
Paclitaxel (PTX) is one of the most commonly used chemotherapy agents approved to treat 
numerous types of cancers, including ovarian cancer, lung cancer, breast cancer, and several 
others. However, one serious limitation to PTX is its poor-water solubility (< 0.1 μg/mL). Thus, 
extensive research has been conducted to develop a formulation to deliver this drug effectively. 
Taxol®, a clinically approved formulation for PTX (Cremophor EL and dehydrated ethanol 1:1), 
solves the solubility issue of PTX; however, it causes many adverse reactions, such as severe 
hypersensitivity reactions, nephrotoxicity, neutropenia, and neurotoxicity. In this study, novel 
solid lipid nanoparticles (SLNs) which are able to solubilize PTX and simultaneously avoid 
unwanted side effects are introduced. SLNs are composed of a solid lipid core of 
farnesylthiosalicylate (FTS) conjugated to ethylene glycol. This lipid is solid at room 
temperature, with a melting point of 52 °C. FTS is a hydrophobic compound that acts as a potent 
and non-toxic Ras antagonist. The hydrophobic SLN core interacts with PTX, allowing for its 
encapsulation with a loading efficiency of ~90%. Moreover, PTX-SLN is surface-decorated with 
PEG5k to enable the nanoparticles to avoid opsonization and circulate in the blood for a longer 
period of time. The PEGylated SLNs were spherical in shape with sizes ranging between 150 to 
200 nm, as determined by Transmission electron microscopy (TEM) imaging and Dynamic Light 
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Scattering (DLS), respectively. The formulation is stable for 2 months at 4 °C. PTX-SLNs 
exhibited significantly improved release kinetics when compared to Taxol®. An in vitro 
cytotoxicity study using three cancer cell lines (PC3, DU145, and 4T1.2) showed comparable 
growth inhibition activity when compared to free PTX. The in vivo anticancer activity in the 
syngeneic murine breast cancer model suggests that PTX-SLNs significantly inhibit tumor 
growth much more effectively than Taxol formulation. Moreover, histological analysis revealed 
that PTX-SLNs caused more tumor cell apoptosis when compared to Taxol formulation. PTX-
SLNs represent a promising delivery system for PTX, thereby highlighting the potential for 
improved therapeutic efficacy in cancer treatments while avoiding the hypersensitivity issues of 
Taxol. 
 
1.2.2. Introduction 
Paclitaxel (PTX) is one of the most commonly used chemotherapy agents, and is derived from 
the bark of Taxus brevifolia (northwest Pacific Yew Tree). PTX is an antimitotic drug, which 
interferes with cancer cell multiplication by stabilizing and preventing microtubules from  the 
disassembly which leads to cell apoptosis (Wani et al., 1971). Paclitaxel has broad-spectrum 
applications in the treatment of various human malignancies, including breast, lung, and ovarian 
cancer. However, PTX’s clinical use has been hindered by its very poor water solubility. Thus, 
extensive research has been conducted to develop a formulation for PTX delivery (Goldspiel, 
1997; Xie et al., 2007; Duan et al., 2010b; Zhang et al., 2014c; Zhang et al., 2015b). Taxol is an 
FDA-approved paclitaxel formulation, which involve the use of 50:50 (v/v) mixture of 
Cremophor EL and dehydrated alcohol. It has solved the solubility issue of PTX. Unfortunately, 
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a major drawback of this formulation lies in its association with serious hypersensitivity 
reactions caused by Cremophor EL (Gelderblom et al., 2001a). Therefore, considerable effort is 
necessary in the development of safer PTX delivery alternatives free from Cremophor EL.  
Solid lipid nanoparticles (SLNs) are a new generation of microemulsions in which liquid 
lipid is replaced by a sold lipid that has a melting point higher than room temperature. SLNs 
were first introduced in the early 1990s as an alternative delivery system to traditional carriers 
(Muller et al., 2000b; Mehnert and Mader, 2001). In recent years, increased attention has been 
directed toward SLNs due to their potential benefits over other carriers. The advantages of SLNs 
include enhanced stability, protection of carried drugs from chemical degradation, sustained 
release kinetics, enhanced bioavailability of encapsulated drugs, and scale up feasibility 
(Mehnert and Mader, 2001; Patel et al., 2014).  
Recently, several studies have reported a variety of SLNs formulations composed of 
physiological lipids for anticancer drug delivery. However, most of these SLN excipients are 
biologically inactive (Mehnert and Mader, 2001; Radomska-Soukharev, 2007; Naguib et al., 
2014b). The replacement of non-functional materials with therapeutically active ones in 
nanocarriers has been evidenced to provide potential synergy with loaded drugs. For instance, d-
α-tocopheryl polyethylene glycol succinate (TPGS), consisting of vitamin E as part of the carrier, 
has demonstrated a dual function via synergizing with delivered anticancer drugs and enhancing 
their solubility (Zhang and Feng, 2006). Our group has recently developed additional dual 
functional micellar systems consisting of polyethylene glycol conjugated with hydrophobic drugs 
which possess other mechanisms of action (Huang et al., 2012; Zhang et al., 2013b; Lu et al., 
2014a).  
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The aim of this study is to design a PTX-SLN formulation with dual functional ability 
using Ethylenegylcol-FTS2 as the solid lipid, decorated with a layer of PEG5k-FTS2. FTS is a 
potent inhibitor of Ras-mediated signaling. Mutation in the Ras gene can lead to permanent 
activation of Ras proteins, resulting in the overactive Ras signaling which ultimately leads to 
cancer. This phenomenon is evident in over 20% of total human malignancies and 90% of 
pancreatic cancer. FTS functions via the dislodgement of Ras proteins from the plasma 
membrane, promoting its degradation (Marom et al., 1995a; Haklai et al., 1998b). We 
hypothesized that encapsulating PTX in an SLN formulation equipped with FTS, both in the core 
and inner phase of outer PEG coating, will provide strong stabilization of PTX within the 
formulation and enhance its loading efficiency. Moreover, this formulation may provide a 
potential synergy between drug and carrier that could enhance treatment outcomes in cancer 
therapy. The new PTX-SLNs were characterized with respect to their particle size, loading 
capacity, and in vitro drug release kinetics. In vitro and in vivo antitumor activity was also 
investigated. 
1.2.3. Materials and methods 
PTX (98%) was purchased from AK Scientific Inc. (CA, USA). FTS was synthesized according 
to the published literature (Marom et al., 1995a). Soy PC (95%) was purchased from Avanti 
Polar Lipids, Inc. (Alabaster, AL, USA). 4-Dimethylaminopyridine (DMAP) was purchased 
from Calbiochem-Novabiochem Corporation (CA, USA). Dulbecco’s phosphate-buffered saline 
(DPBS) was purchased from Lonza (MD, USA), and fetal bovine serum (FBS) and penicillin-
streptomycin solution were purchased from Invitrogen (NY, USA).  The following chemicals 
were purchased from Sigma-Aldrich (MO, USA): Ethylene glycol anhydrous, 99.8%, succinate 
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anhydride, diethanolamine, poly (ethylene glycol) methyl ether (MeO-PEG-OH, Mw = 5000 
kDa), tween 80, poloxamer 188, trimyristin (TM), N-hydroxysuccinimide (NHS), 
dicyclohexylcarbodiimide (DCC), dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl tetrazolium bromide (MTT), and Dulbecco’s modified Eagle’s medium (DMEM). All 
solvents used in this study were HPLC grade. 
 
1.2.3.1. Cell lines and animals 
4T1.2 (mouse metastatic breast cancer cell line), PC-3, and DU-145 (human prostate 
cancer cell lines) were cultured in DMEM supplemented with 10% FBS and 1% 
penicillin−streptomycin at 37 °C and incubated in a humid atmosphere with 5% CO2. Female 
BALB/c mice, 4−6 weeks in age, were purchased from Charles River (Davis, CA). All animals 
were housed under pathogen-free conditions according to AAALAC guidelines. All animal-
related experiments were performed in full compliance with institutional guidelines and 
approved by the Animal Use and Care Administrative Advisory Committee at the University of 
Pittsburgh. 
1.2.3.2. Synthesis of EG-FTS2 lipid 
EG-FTS2 was synthesized via a conjugation reaction of the carboxylic terminal of FTS 
(2.2 eq) with both hydroxyl terminals of EG (1eq), in the presence of DCC as a coupling reagent 
and DMAP as a catalyst at 37 °C in DCM for two days. The reaction mixture was filtered 
through cotton and extracted in a mixture of ethyl acetate and 1N HCL. EG-FTS2 was then 
purified by silica gel. EG-FTS2 purity was confirmed by H+ NMR, and the melting point was 
determined by DSC. 
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1.2.3.3. Synthesis of PEG5K-FTS2 conjugate 
PEG5K-FTS2 conjugate was synthesized via solution condensation reactions from PEG 
methyl ether (mPEG-OH) with a molecular weight of 5000, following a previously reported 
method by Zhang et al. with modification (Zhang et al., 2013b). First, mPEG5k-OH (1 eq) was 
reacted with succinic anhydride (5 eq) and DMAP (5 eq) in DCM at 70°C for 48 h. The PEG 
product was purified by washing with 10 volume of cold ethanol to remove excess DMAP, 
followed by precipitation in cold ether. This cycle was repeated three times, (yield = 91%). 
mPEG5K−COOH (1eq) was then reacted with diethanolamine (3 eq) using NHS (3.6 eq) and 
DCC (3.6 eq) in DCM for 1 day. The derivatized polymer was purified as described in previous 
step and concentrated under vacuum. FTS (6 eq) was then conjugated with the two hydroxyl 
terminals in mPEG5k-(OH)2 (1 eq), aided by DCC (6 eq) and DMAP (0.2 eq), dissolved in DCM 
and allowed to react for 1 day at room temperature. The solution was filtered and purified with 
three cycles of ethanol/ether as mentioned above and concentrated under vacuum. 
1.2.3.4. Preparation of SLNs 
The PTX-SLNs were prepared according to a modified emulsion/solvent evaporation 
method (Ye et al., 2008; Naguib et al., 2014b). Briefly, PTX, EG-FTS2, SPC, and PEG5K-FTS2 in 
a weight ratio of 1:10:5:2.5 were dissolved in 100 µL DCM in a glass tube. One mL of 
Poloxamer 188 aqueous solution was then added and the mixture was sonicated in ice with a 
probe sonicator at 6 W for 30 min. The emulsion was then stirred at 600 rpm in an oil bath at 
70°C for another 30 min to allow for lipid melting, mixing with other ingredients, and 
evaporation of DCM. SLNs were stirred at room temperature for 30 min, and placed in a vacuum 
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pump to remove remaining traces of DCM. SLNs were then sonicated for 10 min to be clear of 
aggregates caused by vacuum pressure, followed by lyophilization with 9.25% (w/v) sucrose as 
cryoprotectant. The final form of PTX-SLNs was obtained by reconstitution of the resulting 
lyophilized powder in 1 mL DPBS. The drug-free SLNs were similarly prepared as described 
above. 
1.2.3.5. Characterizations of SLNs 
1.2.3.5.1. Particle size analysis 
The particle size of SLNs was determined using a Zetasizer (DLS) (Zetasizer Nano ZS 
instrument, Malvern, Worcestershire, UK). Briefly, 20 μL of SLN suspension was diluted to 1 
mL with water, and particle size was measured at room temperature. 
1.2.3.5.2. Determination of drug content, entrapment efficiency (EE) and loading 
capacity (LC) 
To determine the drug loading efficiency of PTX-SLNs, 10 μL was dissolved in 0.5 mL 
methanol, vortexed, and centrifuged at 12000 rpm at 4°C for 10 min. The supernatant was 
collected and drug content was quantified by high performance liquid chromatography (HPLC) 
(Alliance 2695− 2998 system). The reverse-phase Lichrospher 100 RP-18 (5 μm) column was 
used, and the mobile phase consisted of methanol/water (65:35 v/v). The flow rate was set to 0.5 
mL/ min and the detection wavelength was 227 nm. Drug entrapment efficiency (EE) and 
loading capacity (LC) were calculated as follows: 
            EE (%) = (weight of loaded drug/weight of input drug) × 100% 
            LC (%) = [(weight of drug loaded/ (weight of SLN + drug used)] 100%  
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1.2.3.5.3. Differential scanning calorimetry (DSC) 
DSC thermal analysis was performed using a Mettler Toledo DSC. Lyophilized samples 
of PTX, EG-FTS2, drug-free SLNs, and PTX-SLNs were accurately weighed (3 to 8 mg) and 
sealed in an aluminum crucible. The crucible was placed in the DSC device and purged with 
inert nitrogen gas at a rate of 50 mL/min. An empty crucible was used as a reference. 
Thermograms were obtained by heating samples from 35°C to 230 °C at a heating rate of 5 
°C/min.  
1.2.3.5.4. Surface morphology by TEM 
The morphology of SLN formulation was examined for both drug-free and PTX-loaded 
forms via TEM imaging. SLNs samples were stained using a copper grid with Formvar 
immersed in a drop of sample solution and stained with 1% uranyl acetate. Imaging was 
performed at room temperature on JEOL JEM-1011. 
1.2.3.5.5. Stability 
Freshly prepared SLNs were stored in parafilm-sealed glass tubes at 4°C. Changes in 
sizes were monitored by DLS. 
1.2.3.6. In Vitro release of PTX from SLNs 
The kinetics of PTX release from the PTX-SLNs formulation was examined following 
the method by Zhang et al. (Zhang et al., 2013b). Briefly, 2 mL PTX-SLN emulsion or Taxol 
solution (1 mg/ mL) was placed into a dialysis bag (MWCO = 12 kDa, Spectrum Laboratories). 
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The dialysis bag was placed in a beaker with 200 mL DPBS (pH=7.4) containing 1% (w/v) 
Tween 80 (reported PTX solubility in this medium is 13.8 µg/mL) (Kilfoyle et al., 2012). The 
beaker was incubated at 37 °C in an oven and agitated using an orbital shaker at 100 rpm. At a 
predetermined time points, samples were withdrawn from inside the bag and replaced with an 
equivalent volume to maintain sink condition. PTX concentrations were quantified by HPLC 
(Alliance 2695–2998 system). The reverse-phase Lichrospher 100 RP-18 (5 μm) column was 
used and the mobile phase consisted of methanol/water (65:35 v/v). The flow rate was set at 0.5 
mL/min and the column effluent was detected at 227 nm with a UV/vis detector. Values were 
reported as the means from triplicate samples. 
1.2.3.7. In vitro cytotoxicity study 
To investigate the cytotoxicity of the PTX-SLNs formulation, DU145, PC-3, or 4T1.2 
(2000 cells/well) were seeded in 96-well plates. Cells were incubated overnight in 10% FBS and 
1% streptomycin−penicillin, and media was replaced with new media containing various PTX 
formulations of indicated concentrations and cells were continuously cultured for 72 h. Then, 20 
µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) in DPBS was added 
to each well and cells were further incubated for 3.5 h. The medium was gently removed and 
DMSO was added to solubilize MTT formazan, resulting in a purple-colored solution. 
Absorbance was quantified by a microplate reader at a wavelength of 550 nm and reference 
wavelength at 630 nm. Untreated groups served as controls. Cell viability was calculated as 
[(ODtreat − ODblank)/(ODcontrol − ODblank) × 100%].  
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1.2.3.8. In vivo antitumor activity of PTX-SLNs 
 
The in vivo tumor growth inhibition effect of PTX-SLN was evaluated using a syngeneic 
murine breast cancer model (4T1.2). Female BALB/c mice were inoculated subcutaneously at 
the upper right flank with 200 μL (1 × 105) 4T1.2 cells. The day when tumor volume reached 
∼50 mm3 was designated as “day 1”. Mice were randomly divided into five groups (n = 4) and 
administered with i.v. injections of DPBS (control), drug-free SLNs, Taxol, PTX-EG, PTX-TM 
(FTS-free SLNs formulated with trimyristin lipid and PEG5K-OA2 instead of EG-FTS2 lipid), and 
PEG5K-FTS2, respectively. The PTX dosage was 10 mg/kg body weight. Injections were 
repeated on day 3, 5, 8, and 11. Drug-free SLNs were given at an equivalent dosage of carrier in 
the PTX-EG group. The tumor sizes were monitored three times a week using a digital caliper 
and the tumor volumes were calculated using the following equation: (L × W2)/2, where L is the 
longest and W is the shortest diameter in tumor (mm). On day 18, mice were euthanized and 
tumor tissues were harvested, weighed, and fixed in a formalin buffer for histological 
examinations. 
  
1.2.3.9. Histological analysis 
 
Tumors collected from mice were fixed in 10% formalin at 4°C for two days. Each 
sample was cut and gradually dehydrated in ethanol and xylene and then embedded into paraffin. 
The paraffin-embedded tumor samples were sectioned into slices at 6 μm using an HM 325 
Rotary Microtome, and stained with hematoxylin and eosin (H.E).  
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1.2.3.10. Statistical Analysis 
In all statistical analyses, the significance level was set at a probability of P < 0.05. All 
results were reported as the mean ± standard error (SEM) unless otherwise indicated. Statistical 
analysis was performed using Student’s t test for two groups, and one-way ANOVA for multiple 
groups, followed by the Newman-Keuls test if P < 0.05. 
1.2.4. Results 
1.2.4.1. Preparation and characterization of SLNs 
After successfully synthesizing FTS-based lipid conjugates (EG-FTS2), the structure was 
confirmed by 1H NMR. Additionally, DSC confirmed the lipid melting point at 52.89 °C. SLNs 
were prepared using an emulsion/solvent evaporation method. The emulsion was composed of 
PTX, EG-FTS2, SPC, and PEG5K-FTS2 dispersed in the aqueous solution Poloxamer 188. The 
LC%= 5.4%. DLS measurements indicate that drug-free SLNs and PTX-SLNs had an average 
size of ∼150 nm with PDI = 0.156 and ∼190 nm with PDI = 0.239, respectively. Moreover, 
TEM observations showed spherical nanoparticles and the sizes on TEM were consistent with 
those determined by DLS (Figure 4). 
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Figure 4. Particle size distribution of SLNs. 
Drug-free SLNs (A) and PTX-SLNs (C) as determined by DLS. TEM images of drug-free-SLNs (B) and PTX-
SLNs (D). 
DSC was used to analyze the physical state of core lipids in SLN formulations (Figure 5). 
DSC thermograms of PTX revealed a characteristic endothermic melting peak at 217.5°C. This 
peak completely disappeared in PTX-SLNs formulation, indicating the presence of PTX in the 
core of SLN formulations. In addition, thermograms indicated sharp endothermic peaks of EG-
FTS2, drug-free SLNs, and PTX-SLNs at 52.89°C, 52.28°C, and 52.15°C, respectively. These 
peaks indicate the presence of lipids in solid crystalline nature, and confirm the solid state of 
lipids within SLNs. 
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Figure 5. DSC thermograms. 
PTX [red], PTX-SLNs [black], Drug free-SLNs [green], and EG-FTS2 bulk lipid [blue]. 
 
The SLNs stability was followed for two months. Samples were stored at 4°C and the 
particle size distribution of both drug-free and PTX-SLNs were measured daily. As shown in 
Figure 6, no obvious changes in size were found for both formulations, indicating an excellent 
stability PTX-SLNs at 4°C. 
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Figure 6. Size distribution of SLNs. 
Freshly prepared drug free- SLN (A) and PTX-SLN (B) and their sizes after 60 days (C) and (D), respectively. 
1.2.4.2. In vitro release kinetics of PTX from SLNs 
The release kinetics were examined via a dialysis method and compared to Taxol 
formulation as a control. As shown in Figure 7, ~5% of PTX was released from the SLN 
formulation in the first hour, whereas ~35% was released in the Taxol formulation. Twenty-four 
h later, only ~25% was released from PTX-SLNs compared to 77.5% released from Taxol. This 
release pattern of PTX-SLNs may suggest strong PTX-EG lipid interaction and the ability of the 
SLN formulation to avoid burst release of PTX, as seen in Taxol. Moreover, PTX-SLNs 
demonstrated significantly slower kinetics of PTX release throughout the entire 8 day period. At 
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the end of the experiment, ~88% was released from the PTX-SLNs formulation. In contrast, a 
similar percentage was found in Taxol formulation in as early as 2 days.   
 
Figure 7. PTX release profile from PTX-SLNs and Taxol. 
PTX concentration was 1 mg/mL in both Formulations. Release medium was DPBS (pH 7.4) containing 1% 
(w/v) Tween 80. 
 
1.2.4.3. In vitro cytotoxicity study 
The cytotoxicity was investigated in three cancer cell lines: two human prostate cancer 
cell lines (PC-3 and DU145) and one murine breast cancer cell line (4T1.2). Figure 8 presents the 
cytotoxicity of free PTX compared to PTX-SLNs in cancer cells. The data reveals that PTX-
SLNs exhibited a comparable growth inhibition effect in PC3 cells (Figure 8A), and a slightly 
improved effect in DU-145 (Figure 8B) and 4T1.2 (Figure 8C). Drug free-SLNs showed minimal 
cytotoxicity at similar concentrations used in PTX-SLNs (data not shown). 
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Figure 8. Cytotoxicity of free PTX and PTX-SLNs in vitro 
Human prostate cancer cell lines, PC-3, IC50= 7 and 9 ng/mL, respectively (A) and DU-145, IC50= 4.9 and 9 
ng/mL, respectively (B), and mouse breast cancer cell line 4T1.2, IC50= 4 and 6 ng/mL, respectively (C). 
 
1.2.4.4. In vivo antitumor activity in a mouse model 
The in vivo tumor growth inhibition activity was evaluated in a syngeneic murine breast 
cancer model (4T1.2). As shown in Figure 9A, at a PTX dosage of 10 mg/kg (Taxol, TM-SLNs, 
and EG-SLNs) all exhibited significant inhibition of tumor growth when compared to the control 
group. However, PTX-EG SLNs have shown a clear improvement in antitumor activity when 
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compared to Taxol and PTX-TM formulations, which showed comparable antitumor effect. 
Interestingly, drug free-SLNs alone also exhibited moderate antitumor activity although less 
effectively than PTX-loaded SLNs. This effect may be attributed to the accumulation of FTS 
already present in the formulation at tumor sites. Figure 9B show the weights of tumors removed 
at the end of experiments, which were consistent with the data in tumor growth curves (Figure 
9A). No changes in body weight were noticed among all treatment groups (Figure 9C).  
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Figure 9. In vivo antitumor activity in a mouse model 
(A) In vivo antitumor activity of PTX-SLNs. BALB/c mice (n = 4) were inoculated s.c. with 4T1.2 cells 
(2×105 cells/mouse). One week later, mice were treated with various agent indicated above on days 1, 3, 5, 8, 
and 11, and tumor growth was monitored and plotted tumor volume (mm3). *P <0.05 (PTX-EG vs. Taxol). 
**P <0.01 (PTX-EG vs. Taxol). (B) body weight changes in all groups. (C) Tumors of different groups were 
excised at the end of experiment. Average weight were measured and plotted, and tumor growth inhibition 
rate (IR) was calculated as : (1 − (mean tumor weight of drug treated group/mean tumor weight of saline 
treated group)) * 100% 
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1.2.4.5. Histological analysis 
To further illustrate the therapeutic effect of PTX-SLNs, histological analysis was 
conducted using H.E staining. Upon completion of the experiment, tumor samples were excised, 
fixed into paraffin wax, and thin slices were stained and observed under a light microscope. As 
depicted in Figure 10, tumors in DPBS-treated group consisted of tightly packed tumor cells, 
indicating uncontrolled tumor proliferation. A decreased tumor cell density with signs of 
apoptotic cells was observed in tumors treated with drug-free SLNs. In consistent with growth 
inhibition curves, PTX-SLNs exhibited the highest level of necrotic/apoptotic tumor cells when 
compared to Taxol and PTX-TM groups. 
Figure 10. H.E staining of tumor tissues after completion of experiment (18 days) 
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1.2.5. Discussion 
This study involved the development of a novel form of solid lipid nanoparticles which 
effectively solubilize PTX. EG-SLN formulation is composed of a synthetic EG-FTS2 lipid as a 
solid core, and PEG5k-FTS2 conjugate as shielding molecule. Most importantly, this FTS-based 
material readily formulated SLNs which can load and deliver PTX.  
Most reported SLNs formulations use physiological lipids such as pure glycerides or wax 
as solid core (Jenning and Gohla, 2000). Although these excipients are considered safe, they do 
not provide any beneficial therapeutic effect alone. On the other hand, these FTS-based SLNs act 
as a dual functional carrier that may achieve these goals. FTS is a potent and non-toxic Ras 
antagonist which is being extensively studied as a new agent for cancer therapy. FTS also 
exhibits an excellent safety profile among other chemotherapeutic agents (Kloog et al., 1999; 
Blum and Kloog, 2005; Haklai et al., 2008). In addition, several studies have reported that FTS 
may provide a synergistic effect for cancer treatment when combined with other anticancer 
agents (Biran et al., 2011; Mologni et al., 2012; Chen et al., 2014).  
A unique advantage of EG-SLNs is their small particle size (150-200 nm). As reported in 
the literature, this size fits in the optimal size range (100-200 nm) for drug delivery systems, 
allowing for effective passive targeting via EPR effect (Li and Huang, 2008).  Moreover, EG-
SLNs presented an excellent stability profile for 2 months at 4°C, which may indicate strong 
interaction between PTX and FTS hydrophobic moieties present in both EG-FTS2 and PEG5k-
FTS2. The absence of PTX’s characteristic melting peak in PTX-SLNs formulations, this is 
supported by the data from DSC study, indicates that PTX loses its crystallinity as a result of 
strong interactions between drug and carrier.  
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The release kinetics of PTX from SLNs was significantly slower compared to Taxol 
formulations (Figure 7). The t1/2 of Taxol was 12.5 h, while the t1/2 of PTX-SLNs was 76 h. The 
PTX-SLN formulation was also able to avoid early burst release when compared to Taxol. 
Additionally, PTX-SLNs exhibited a sustained release rate after the 24 h’ time-point. The 
biphasic release behavior observed here (between 0-4 h and 4-200 h) may be attributed to the 
small fraction of PTX that is present on the surface of SLNs’core which might have relatively 
weaker interaction with the core. These data support the hypothesis that the incorporation of FTS 
in the core and outer layer of SLNs should provide strong drug/carrier interaction, leading to 
enhanced drug loading and stability. This interaction may be attributed to the hydrophobic 
interaction between PTX and FTS, along with π−π stacking of benzene rings of both compounds, 
and hydrogen bonding mediated by the acyl groups of FTS. More studies are needed to further 
elucidate the mechanism of interaction between drug and carrier.  
In vitro cytotoxicity in three cell lines (PC3, DU-145, and 4T1.2) indicates that PTX-
SLNs retains its anticancer activity by showing similar or slightly higher killing effect  when 
compared to free PTX dissolved in DMSO. This suggests that PTX-SLNs were effectively taken 
up by cells. Considering the slow kinetics of drug release, perhaps not all of PTX was released 
from SLNs during the short period of cytotoxicity study. Therefore, the cytotoxic effect of PTX-
SLNs might be underestimated.  
An aggressive metastatic murine breast cancer model (4T1.2) was used to study the 
therapeutic effect of PTX-SLNs in vivo. PTX-TM SLNs formulation was included as an inert 
carrier to study the contribution of PTX to overall therapeutic effect of PTX-loaded SLNs in the 
formulation. PTX-TM SLNs consists of trimyristin, a solid lipid with a melting point of 57 °C, 
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which is coated with PEG5k-OA2. PTX-SLNs exhibited improved anticancer activity when 
compared to Taxol and PTX-TM formulations, although these results are not statistically 
significant. This is likely due to enhanced antitumor activity caused by FTS incorporation in the 
system. FTS improves drug stability within SLN formulations, which improves tumor delivery, 
leading to enhanced bioavailability. Also, FTS may synergize with PTX which may contribute to 
the overall anticancer activity. Finally, PTX-SLNs were well tolerated in mice as evidenced by a 
similar body weight when compared to control mice.  
 
1.2.6. Conclusion 
We have successfully developed FTS-based SLNs that efficiently solubilize and deliver PTX. 
PTX-SLNs formed spherically shaped NPs with small particles sizes (< 200 nm) and 
demonstrated an excellent stability at 4°C. Moreover, this system exhibits a sustained kinetics of 
drug release and improved in vivo antitumor activity when compared to Taxol. PTX-SLNs may 
represent a promising SLN system that could avoid the hypersensitivity issue of current 
formulations, and provide a potential synergy with co-delivered anticancer drugs in overall 
therapeutic activity. Additional studies are required to better understand the mechanism of 
interaction between drug and carrier for future carrier improvements.  
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1.3. CONCLUSION AND PERSPECTIVES 
The battle against cancer represents one of greatest challenges in modern history. It is expected 
that cancer may surpass heart diseases as the leading cause of death in the United States within 
the coming years. However, our strategies to face this fight are developing rapidly, and 
knowledge regarding cancer is growing due to the ongoing advancement of medical tools. When 
compared to other classes, chemotherapeutic drugs, especially cytotoxic agents, are the most 
reactive, toxic, and unstable options due to their diverse structures and physicochemical 
properties. The application of nanotechnology has greatly overcome many challenges of 
chemotherapy agents and maximized their potential therapeutic benefits. The development of NP 
delivery systems has grown over the past decades. This development is expected to have a 
significant impact on future cancer therapy due to more favorable tumor-specific targeting and 
controlled release of payload drugs. 
Given its unique flexibility, an increased amount of research has been devoted to the 
study of SLNs system over the past decade. In this chapter, we have experimentally 
demonstrated that SLNs can be further rendered dual-functional via incorporation of a FTS-
based solid lipid. The drug release rate and in vivo anticancer activity have been significantly 
improved when compared to the clinically available PTX formulation (Taxol). Future 
improvement of SLN systems may result in the development of new generation of anticancer 
nanocarriers that outperform the ones currently being used. SLN improvement may include the 
development of dual functional nanocarriers that work synergistically with anticancer agents. 
Also, decorating NPs with both PEG and a tumor-specific ligand in a more effective manner will 
achieve higher tumor targeting ability. Moreover, further investigations into the mechanism of 
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interaction between carrier and drug, along with in vivo carrier behavior, will enrich overall 
understanding and improve the formulation capabilities for clinical applications.  
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2. THYMOQUINONE TARGETED THERAPY FOR LIVER FIBROSIS 
2.1. INTRODUCTION 
Liver fibrosis is defined as an excessive accumulation of extracellular matrix proteins (ECM) in 
response to acute or chronic liver injury. Progression of liver fibrosis leads to a more serious 
condition called cirrhosis, where most of the liver cells are replaced by scar tissues and 
ultimately resulting in organ failure. Liver cirrhosis is currently the 12th leading cause of death in 
the United States, accounting for 32,000 deaths per year (Murphy et al., 2013).  In the past, liver 
fibrosis was considered an irreversible condition due to hepatic parenchyma collapse and the 
massive accumulation of collagen scarring. Currently, liver fibrosis is recognized as wound 
healing model response (Benyon and Iredale, 2000a). In acute liver injury, the healing response 
can completely recover liver damage in a relatively short time, even if a large portion of the liver 
is destroyed. However, in chronic injury, the liver experiences repetitive damage which causes a 
loss of regenerative capacity and chronic wound healing response, which includes necrosis 
and/or apoptosis of parenchymal cells and leads to their replacement by scar tissue. The wound 
healing process is beneficial in acute injuries, yet, it becomes a pathogenic condition in chronic 
injures if it continues without treatment (Bataller and Brenner, 2005; Lee et al., 2015). In 
industrialized countries, the most common causes of liver fibrosis are hepatitis C virus (HCV), 
heavy alcohol consumption, and nonalcoholic steatohepatitis (Friedman, 2003a). Other diseases, 
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such as autoimmune diseases, drug-induced liver disease, and trauma can also contribute to the 
incidence of liver fibrosis (Friedman, 2003a; Rockey and Friedman, 2007). Currently, the only 
effective treatment is the removal of the underlying cause, such as eradication of viral infection, 
or immunosuppressive treatment of autoimmune liver disease (Hammel et al., 2001; Kweon et 
al., 2001; Poynard et al., 2002; Farci et al., 2004). An accumulating amount of evidence shown 
in animal studies supports the concept that liver fibrosis and cirrhosis are reversible conditions 
(Dufour et al., 1997a; Iredale et al., 1998; Benyon and Iredale, 2000a). However, the chances of 
reversibility are much higher in fibrosis, and the possibility of resolution becomes increasingly 
difficult as the disease progresses toward cirrhosis (Friedman, 2003a). Therefore, focusing on the 
development of anti-fibrotic therapies holds huge promise toward finding a cure for the disease, 
considering the long progression time (an estimated 20-30 years) until the development of 
cirrhosis (Benmanov and DiMartino, 2000; Thein et al., 2008). 
Following liver injury, major changes take place in the liver microenvironment, resulting 
in changes in the phenotype of all liver cells. Among the cells contributing to the production of 
extracellular matrix proteins (ECM) following liver insult, hepatic stellate cells (HSCs) represent 
a key fibrogenic effector cell type, whose significant role in the pathology of liver fibrosis has 
been well clarified. Thus, these are the target cells for anti-fibrotic therapies (Wu and Zern, 2000; 
Fallowfield, 2011; Mederacke et al., 2013). HSCs, also known as perisinusoidal cells or Ito cells, 
reside in the space of Disse (a small area between the sinusoids and hepatocytes). Under normal 
physiological conditions, HSCs (referred as quiescent HSCs), which represent ~15% of the total 
liver cells population, are considered the principle storage site for vitamin A (Wang, 1999; 
Bataller and Brenner, 2005; Friedman, 2008). Also, these cells perform a key role in the 
maintenance of steady-state levels of basement membrane-like matrix, in addition to the 
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regulation of hepatic blood flow and portal venous pressure (Moreira, 2007b). After chronic 
injury exposure to the liver, inflammatory lymphocytes infiltrate liver parenchyma, and some 
injured hepatocytes undergo apoptosis. Apoptotic hepatocytes release cytokines and reactive 
oxygen species, which in turn activate liver macrophages (Kuppfer cells) to release pro-
inflammatory factors such as transforming growth factor-(TGF-β), platelet-derived growth factor 
(PDGF), and tumor necrosis factor-α (TNF-α) (Wu et al., 1998). These changes promote the 
HSCs to undergo dramatic phenotypic transformation, termed activation, into myofibroblast-like 
cells. Activated HSCs lose their vitamin A content and transition into proliferative, fibrogenic, 
proinflammatory, and contractile cells which determine the overproduction of ECM (mainly 
collages type I and III) (Iredale et al., 1998; Friedman, 2004). The contractile feature also plays 
pivotal role in promoting portal hypertension, which facilitates further progression toward 
cirrhosis. During the resolution of liver fibrosis, HSCs may revert back to the quiescent state or 
undergo selective clearance by apoptosis (Iredale et al., 1998; Friedman, 2004). Therefore, 
agents that inhibit or interfere with the activation process or selectively induce apoptosis are of 
great interest for their significant impact on the treatment of liver fibrosis.   
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2.2. OVERVIEW OF TQ THERAPEUTIC APPLICATIONS 
Due to the limitations of conventional medicine represented in severe and unwanted side effects, 
increased attention has shifted toward the discovery of therapeutic compounds with natural 
origins. Over the last decades, the focus on discovering medicinal plants has increased 
considerably in an effort to find replacements for synthetic drugs, or at least serve as adjunctive 
therapy to reduce the toxicity of primary drugs. Among these promising plants is Nigella sativa 
(or black seed). This species has traditionally been known to treat a variety of diseases for over 
2000 years (Yi et al., 2008). Moreover, it is more commonly used as a condiment and spice in 
middle and far eastern countries. Thymoquinone (2-isopropyl-5-methylbenzo-1, 4-quinone) (TQ) 
is the active component of Nigella sativa and constitutes ~ 30% of its volatile oil (Al-Ali et al., 
2008b)(see TQ structure in Figure 11). Since the extraction of TQ (el-Dakhakhny, 1965), 
numerous research has been conducted to explore its therapeutic potential for many diseases 
(Houghton et al., 1995; Badary et al., 1997; Mutabagani and El-Mahdy, 1997; Nagi et al., 1999b; 
Badary and Gamal, 2000). TQ exhibited a wide spectrum of biological activities in inflammatory 
diseases and cancer. TQ holds great potential as an antioxidant agent; in addition, it has array of 
favorable effects, including anti-inflammatory (Mutabagani and El-Mahdy, 1997), antitumor 
(Majdalawieh et al., 2010; Aikemu et al., 2013), hepatoprotective (Al-Suhaimi, 2012; Talib and 
Abukhader, 2013), antidiabetic (Fararh et al., 2005; Al Wafai, 2013), and antibacterial activities 
(Kokoska et al., 2008; Bakathir and Abbas, 2011). TQ mechanisms of action are complex due to 
multiple activities having been observed in a wide range of diseases. The antioxidant ability of 
TQ resides in its scavenging effects against reactive oxygen species (ROS), such as superoxide 
anion, hydroxyl radical, and singlet molecular oxygen, which are elevated in various diseases 
(Nagi and Mansour, 2000; Mansour et al., 2002). In cancer, TQ shows promising antitumor 
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activity in multiple cancer types, with the advantage of minimal toxicity against normal cells 
(Shoieb et al., 2003). Additionally, TQ has demonstrated inhibition of breast cancer in vitro, and 
enhanced the antitumor activity of doxorubicin and 5-florouracil when combined with TQ. These 
studies have revealed the anticancer activity of TQ through enhanced PPAR-gamma activity and 
downregulation of several pro-apoptotic genes, including Bcl-2, Bcl-xL, and survivin (Woo et 
al., 2011). Moreover, a number of studies have reported TQ’s hepatoprotective and anti-fibrotic 
effects in vitro and in vivo (Badary et al., 1999; Nagi et al., 1999b; Nagi et al., 2010; Bai et al., 
2013a). Daba and Abdel-Rahman showed that TQ possessed hepatoprotective properties similar 
to those seen in Silybin (part of the Silymarin flavonoid complex), a known hepatoprotective 
agent with antioxidant properties. TQ protected isolated rat hepatocytes against tert-
butylhydroperoxide (TBHP)-induced toxicity, as evidenced by the inhibition of intracellular 
glutathione depletion, protection of cell membrane integrity, and prevention of alanine 
transaminase (ALT) and aspartic transaminase leakage  (Daba and Abdel-Rahman, 1998; 
Kloosterman and Plasterk, 2006). Bai et al. explored the anti-fibrotic activity of TQ in a 
thioacetamide-induced liver fibrosis mouse model. TQ substantially attenuated liver fibrosis 
progression and remarkably decreased ECM accumulation. This study indicated that TQ can 
negatively regulate the expression of toll-like receptor 4 (TLR4), inhibit phosphatidylinositol 3-
kinase (PI3K) phosphorylation, and activate the LKB1-AMPK signaling pathway (Bai et al., 
2014). Amein et al. studied lethal dose (LD50) of TQ in rodents. The reported LD50 of TQ in 
experimental animals was as follows: in mice, 104.7 mg/kg, injected intra-peritoneally (i.p.), and 
870.9 mg/kg orally; and in rats, 57.5 mg/kg injected i.p., and 794.3 mg/kg orally. These values 
are 10-15 times greater than the reported i.p. dose for antioxidant, anti-inflammatory, and anti-
cancer activity, and 100-150 times greater for oral dose. These data suggest that TQ is relatively 
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safe in experimental animals, especially when administered orally (Al-Ali et al., 2008a). 
Moreover, Al-Amri and Bamosa (2009) conducted a phase I study in 21 patients with solid 
tumors or hematological malignancies for oral TQ. They reported no significant systemic 
toxicities; with marginal decreases in tumor markers of no more than 25% of baseline levels. 
This study also discovered that up to 2600 mg/day of TQ was tolerable (Al-Amri and Bamosa, 
2009). In general, these studies suggest that TQ is one of promising candidates for liver fibrosis 
therapy with wide margin of safety in humans. 
O
O
 
Figure 11. Chemical structure of Thymoquinone (TQ) 
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2.3. ANTI-FIBROTIC EFFECT OF THYMOQUINONE ON HEPATIC STELLATE 
CELLS 
2.3.1. Abstract 
Hepatic stellate cells (HSCs) are the major cells involved in the production of the extracellular 
matrix in liver. Following liver injury, HSCs undergo a transdifferentiation process from a 
quiescent state to an activated state, which plays an important role in liver fibrosis. Previous 
studies have indicated that thymoquinone (TQ) might have a protective effect against liver 
fibrosis in animal models; however, the underlying mechanism of action is not fully understood. 
The aim of this study is to examine whether TQ has any direct effect on HSCs. The results of this 
study indicate that pretreatment of mice with TQ has a protective effect against CCl4-induced 
liver injury when compared to the control (untreated) group; this is consistent with previous 
studies. Moreover, an in vivo study indicated that COL1A1 and α-SMA mRNA levels were 
significantly downregulated by TQ treatment. Similarly, an in vitro study confirmed that TQ 
downregulated COL1A1, COL3A1, and α-SMA mRNA levels in activated rat HSCs and LX2 
cells. Pretreatment with TQ also inhibited the LPS-induced proinflammatory response in LX2 
cells, as demonstrated by the reduced mRNA expression of IL-6 and MCP-1. Mechanistically, 
inactivation of the NF-κB pathway is likely to play a role in the TQ-mediated inhibition of 
proinflammatory response in HSCs. Finally, this study indicates that TQ inhibits the culture-
triggered transdifferentiation of freshly isolated rat HSCs, as shown by the significant 
downregulation of mRNA expression of several fibrosis-related genes. In conclusion, this study 
suggests that TQ has a direct effect on HSCs, which may contribute to its overall anti-fibrotic 
effect. 
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2.3.2. Introduction 
Liver fibrosis is one of the leading causes of morbidity and mortality worldwide (Moreira, 
2007a). Liver fibrosis results from an excessive accumulation of extracellular matrix proteins, 
which represents the liver’s response to injury. Liver fibrosis is not an independent disease, but 
rather an outcome of many chronic liver diseases, such as HCV infection, alcohol abuse, and 
nonalcoholic steatohepatitis (NASH) (Friedman, 2003b; Bataller and Brenner, 2005). Untreated 
liver fibrosis results in progression to cirrhosis, liver failure, and portal hypertension (Bataller 
and Brenner, 2005). Importantly, strong evidence now exists to support the concept of liver 
fibrosis being a reversible condition (Dufour et al., 1997b; Benyon and Iredale, 2000b; Friedman 
and Bansal, 2006b). Therefore, the chances of reversibility at the fibrosis stage are much higher 
than if the condition had progressed to cirrhosis (Friedman, 2003b).  
Currently, no standard treatment exists for liver fibrosis. Removal of the causative agent is still 
considered the most effective therapy (Bataller and Brenner, 2001; Davis et al., 2003; Cheng and 
Mahato, 2007). Within the past decade, a significant amount of progress has been made in 
comprehending the underlying mechanisms of liver fibrosis. It has been well established that 
hepatic stellate cells (HSCs) play a central role in liver fibrosis (Bataller and Brenner, 2001). 
Following liver injury, HSCs undergo an “activation” or transdifferentiation process from 
quiescent vitamin A storing cells to myofibroblast-like cells. This process leads to notable 
changes in the phenotypic features of HSCs, including: increased expression of α-SMA (the 
protein involved in cell motility and contractility), loss of retinoid-storing capacity, enhanced cell 
migration and adhesion, increased proliferation, production of chemotactic proteins, enrichment 
of the rough endoplasmic reticulum,  and acquisition of fibrogenic capacity (Moreira, 2007a; 
Atzori et al., 2009). 
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Thymoquinone (TQ) is the main active constituent of Nigella sativa plant oil, also known 
as black seed or black cumin(Sayed, 1980). TQ is commonly used as a food additive, and has 
been known for its ability to prevent and cure many diseases for centuries (Al-Ghamdi, 2003). 
Several studies have shown that TQ has many pharmacological effects, including antioxidation 
and hepatoprotective effects against hepatotoxins (Nagi et al., 1999a; Mansour, 2000; Ragheb et 
al., 2009; Woo et al., 2012). For instance, pretreatment of mice with TQ led to significant 
decreases in CCl4-induced liver injury, as indicated by histology examination and serum enzyme 
(ALT, AST, and LDH) tests (Anderson and Smith, 2003). A recent study by Oguz et al. (2012) 
suggests that TQ inhibits common bile duct ligation (CBDL)-induced liver damage in rats, 
including fibrotic changes in the liver. So far, the hepatoprotective and anti-fibrotic effects of TQ 
are largely attributed to its antioxidative activity, which leads to decreased hepatocyte damage 
and thus decreased transactivation of HSCs. However, the detailed mechanism remains to be 
completely understood. Particularly, the role of TQ in directly inhibiting the fibrogenic activity 
of HSCs has not been studied. 
In this study, we showed that TQ can protect liver damage induced by CCl4, which is 
consistent with the published work.  This study also indicates that TQ can act directly on HSCs 
via inhibiting their transactivation and the expression of fibrosis-related genes. This study 
unveils a new mechanism which may contribute to the overall anti-fibrotic effect of TQ. 
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2.3.3. Materials and Methods 
2.3.3.1. Animal 
Female CD-1 mice weighing 25g were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Male Sprague-Dawley rats (200-250 g) from Charles River Laboratories 
(Wilmington, MA) were used for HSC isolation. 
2.3.3.2. Chemical  
Lipopolysaccharides (LPS), silymarin (SM), and TQ were purchased from Sigma-Aldrich 
(St. Louis, MO). The purity (GC) of TQ is ≥98.5% as per the manufacturer’s specification. 
Carbon tetrachloride (CCl4) was purchased from Merck (Whitehouse Station, NJ). 
2.3.3.3. Cell line 
LX2, an immortalized human hepatic stellate cell line, was kindly provided by Dr. Scott 
L. Friedman (Mount Sinai School of Medicine, New York, NY)and cultured in Dulbecco's 
modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and antibiotics. 
 
2.3.3.4. Rat HSCs Isolation 
Retired male Sprague-Dawley rats weighing 200-250 g, obtained from Charles River 
Laboratories (Wilmington, MA), were used to isolate HSCs. HSCs were isolated via in situ 
proteinase/collagenase perfusion followed by density gradient centrifugation as described (Li et 
al., 2011). The purity of isolated cells was >90%. Isolated HSCs were cultured in 6-well plate in 
DMEM with 10% FBS and antibiotics for 7 days to allow the process of activation.  
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2.3.3.5. Assessment of TQ protective effect in mice 
Four groups were used (n = 4) in this study; including group A that received no 
treatment, group B that was treated with oral TQ (25 mg/kg dissolved in sesame oil), group C 
that received i.p. injection of CCl4 (dissolved in sesame oil), and group D that received both TQ 
and CCl4 treatment. Mice in groups B and D were treated with TQ daily for 7 days while mice in 
groups C and D received a single dose of CCl4 on day 6. All mice were sacrificed 2 days after 
CCl4 injection. Samples from liver tissues were directly stored in -80°C freezer for gene 
expression study or fixed in 4% paraformaldehyde for histology study. 
2.3.3.6. Mice liver tissue processing 
The liver was sectioned and fixed in phosphate-buffered 10% formaldehyde for 
histological analysis. Each formaldehyde-fixed sample was embedded in paraffin, cut into 5 
micron-thick sections and stained with hematoxylin-eosin (H.E.) and Masson's trichrome 
according to standard procedures. 
 
2.3.3.7. Cytotoxicity assay 
LX2 Cells were seeded in 96-well plate and incubated in DMEM containing 10% FBS 
overnight. Cells were then treated with various concentrations of TQ (in DMSO) for 24 h. Cell 
viability was measured by MTT assay (Roche Diagnostics, Indianapolis, IN) as described 
(Huang et al., 2012).     
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2.3.3.8. RNA isolation and qRT-PCR 
Total RNA was extracted with TRIzol reagent (Invitrogen). The total RNA was measured 
by NanoDrop 2000 (Thermo Scientific). Extracted RNA concentration was adjusted to be 1μg 
per reverse transcription reaction using SuperScript III reverse transcriptase (Invitrogen). The 
primers for COL1A1, COL3A1, α-SMA, MCP-1, IL-6 and GAPDH were obtained from MWG 
Biotech. After synthesis of first strand cDNA, Real-Time PCR was performed using SYBR 
Green-based assays with the ABI Prism 7300 (Applied Biosystems, Foster City, CA) (Li et al., 
2008a).  
2.3.3.9. Assessment of TQ inhibitory effect on LPS-induced proinflammatory 
response in LX2 cells 
LX2 cells were seeded in a 6-well plate in DMEM containing 10% FBS overnight. Cells 
were pretreated with TQ for 24 h, challenged with LPS (100 ng/mL) for 4h, and then were 
harvested with TRIzol reagent. MCP-1 and IL-6 mRNA expression levels were measured as 
described above. 
2.3.3.10. Assessment of TQ inhibitory effect on culture-triggered transdifferentiation, 
and fully activated primary rat HSCs 
Rat HSCs were isolated as described above. Cells were divided into 7 groups: untreated 
cells that were harvested on day 1, vehicle treated cells that were treated with DMSO (0.1%) and 
harvested on day 7, TQ-treated cells that were treated with TQ (4 µM) once every 2 days and 
harvested on day 7, and cells cultured for 7 days followed by treatment with TQ (1 and 4 µM) 
for 24 h, and cells cultured for 7 days followed by treatment with silymarin (10 and 40 µM) for 
24 h. The mRNA expression levels of COL1A1 and α-SMA genes were assessed by qRT-PCR 
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as described above. Similarly, LX2 cells were treated with different concentrations of TQ and 
SM for 24 h, and the mRNA expression levels of COL1A1 and α-SMA genes were assessed by 
qRT-PCR 
2.3.3.11. Western Blot 
Cells were harvested after being washed and lysed in lysis buffer (0.2% Triton X-100) for 
5 min on ice. Cell lysates were collected and centrifuged 12,000 rpm for 10 min at 4 °C. Equal 
amounts of proteins were heated to 95 °C for 5 min in loading buffer and then separated on 10% 
SDS-polyacrylamide gel. The proteins were transferred to polyvinylidene difluoride membranes 
(Thermo Scientific) that were blocked for 1hand then probed overnight at 4°C with an antibody 
specific to p-NF-κB p65 (Santa Cruz Biotechnology, Santa Cruz, CA). Blots were then incubated 
with horseradish peroxidase (HRP)-conjugated secondary antibody. HRP was detected using 
chemiluminescence detection reagent (Denville Scientific Inc). 
2.3.3.12. Statistical analysis 
Values for all measurements are expressed as mean ± SEM. Each experiment was 
performed in triplicate. Comparisons between two groups were made using unpaired Student's t 
test. Differences were considered statistically significant if the P value was less than 0.05. 
 
 53 
2.3.4. Results 
2.3.4.1. TQ protects against CCl4-induced liver damage 
We first investigated TQ protective effect in mice that were pretreated with TQ (25 
mg/kg) for 5 days followed by CCl4 injection. TQ-pretreated group showed significant resistance 
to CCl4-induced injury compared to the group that received only CCl4 (without TQ pretreatment) 
(Figure 12C and D). Mice treated with TQ alone showed normal liver histology similar to 
untreated group (Figure 12A and B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. TQ protects mice against CCl4-induced liver damage. 
Mice (n = 4) received daily TQ treatment orally for 5 days followed by a single injection of CCl4 (i.p.). Liver 
tissues were collected 2 days after CCl4 injection and subjected to H.E. staining. A: Control (untreated), B: TQ 
(25 mg/kg), C: CCl4, and D: TQ pretreatment followed by CCl4 injection. N = 4. Bar represent 100µm 
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   Control              TQ                   CCl4            CCl4+TQ  
                         (25mg/kg)                            (25 mg/kg) 
Control             TQ                   CCl4              CCl4+TQ  
                     (25mg/kg)                            (25 mg/kg) 
 
2.3.4.2. TQ downregulates the mRNA expression of COL1A1 and α-SMA in mouse 
liver  
Following the demonstration of the hepatoprotective effect of TQ, we then investigated 
the effect of TQ on the mRNA expression of COL1A1 and α-SMA in the liver of CCl4-treated 
mice. COL1A1 is the major collagen in fibrotic liver (Friedman et al., 1985) and its mRNA 
expression level was significantly upregulated in the liver of CCl4-treated mice (Figure. 13). TQ 
pretreatment significantly inhibited the CCl4-induced upregulation of COL1A1 mRNA 
expression in mouse liver. TQ similarly inhibited the CCl4-induced upregulation of α-SMA, a 
known marker for HSCs activation (Mabuchi et al., 2004) (Figure. 13). These data suggest that 
TQ exhibits anti-fibrotic activity. 
 
 
Figure. 13. TQ downregulates the mRNA expression of COL1A1 and α-SMA in mouse liver 
TQ significantly downregulates mRNA expression of COL1A1 and α -SMA in the liver of CCl4-treated mice (n = 
4). Mice were treated with TQ followed by CCl4 as described in Figure 12. and mRNA expression of COL1A1 
and α-SMA in mouse liver was determined via qRT-PCR. 
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2.3.4.3. In vitro cytotoxicity of TQ  
The hepatoprotective effect of TQ is likely to play a role in its anti-fibrotic activity due to 
the decreased damage of hepatocytes and subsequent decrease in HSC activation. It was 
hypothesized that TQ also inhibits fibrogenic activity via a direct effect on HSCs. To test this 
hypothesis, the effect of TQ on the proliferation of HSC in vitro was examined, as the induction 
of HSC apoptosis is currently being explored as a therapeutic approach for the prevention and/or 
treatment of liver fibrosis (Hagens et al., 2008). Figure. 14 shows the results of a MTT assay 
with LX2 cells. LX2 is an immortalized human hepatic stellate cell line, and these cells are fully 
activated (Xu et al., 2005). Our results indicate that TQ inhibited the proliferation of LX2 cells in 
a dose-dependent manner. Silymarin showed a minimal effect on the proliferation of HSCs at the 
concentrations used (Figure. 14). 
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Figure. 14. In vitro cytotoxicity of TQ. 
Cytotoxic effect of TQ and SM on LX2 cells. Cells were treated with various concentrations of TQ and 
SM. MTT assay was performed 24 h later. 
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2.3.4.4. TQ downregulates the expression of several fibrosis-related genes in LX2 
cells and culture-activated primary rat HSCs 
Following the demonstration of the growth inhibitory effect of TQ on LX2 cells, we went 
on to further examine the effect of TQ on the mRNA expression of several fibrosis-related genes 
including COL1A1, COL3A1, and α-SMA in both LX2 and culture-activated primary rat HSCs. 
TQ was applied to cells at the concentrations that were shown to have minimal effect on cell 
growth (Figure. 14). As shown in Figure. 15A, TQ inhibited the mRNA expression of all of the 
three genes in LX2 cells in a concentration dependent manner. Moreover, TQ significantly 
downregulated COL1A1 and α-SMA mRNA expression in culture-activated primary rat HSCs as 
shown in Figure. 15B. Similar effects were shown for silymarin at concentrations that were 
nontoxic to the cells (Figure. 15A and B). 
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Figure. 15. TQ downregulates the expression of several fibrosis-related genes in LX2 cells and culture 
activated primary rat HSCs. 
TQ and SM significantly downregulates the mRNA expression of COL1A1 and α -SMA genes in LX2 cells (A) 
and culture-activated primary rat HSCs (B): Cells were treated with TQ and SM in DMEM containing 10% FBS 
for 24 h. Cells were harvested with TRIzol reagent and the mRNA expression of several fibrosis-related genes 
was measured by qRT-PCR. Expression folds were normalized against GAPDH gene expression. 
 
2.3.4.5. TQ suppresses the LPS-induced proinflammatory response in LX2 cells 
It is known that HSCs can produce certain types of chemokines and cytokines in response 
to various types of stimuli, such as Lipopolysaccharide (LPS), which could have both paracrine 
and autocrine effects (Gressner and Weiskirchen, 2006).  LPS is an endotoxin from Gram-
negative bacteria which interact with TLR4 and induce proinflammatory response through 
activation of NF-κB. To examine whether TQ can inhibit the proinflammatory response of HSCs 
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towards LPS, LX2 cells were pretreated with TQ followed by challenge with LPS and the 
mRNA expression of monocyte chemoattractant protein-1(MCP-1) and interlukin-6 (IL-6). As 
shown in Figure. 16, LPS induced significant upregulation in the mRNA expression of both 
MCP-1 and IL-6 genes. Both responses were significantly inhibited when LX2 cells were 
pretreated with TQ. 
 
 
  
Figure. 16. TQ significantly suppresses pro-inflammatory response after LPS challenge. 
Cells were plated in 6-well plates overnight followed by treatment with TQ at 1 and 5µM in DMEM containing 
10% FBS for 24h. Cells were then challenged with LPS (0.1µg/mL) for 4h and the mRNA expression levels of 
MCP-1 and IL-6 were determined by qRT-PCR. 
 
2.3.4.6. TQ inhibits NF-κB activation induced by LPS 
It is known that MCP-1 and IL-6 are two target genes of NF-κB signaling (Libermann and 
Baltimore, 1990; Ueda et al., 1994). Thus, we investigated the effect of TQ on NF-κB signaling 
to elucidate the potential role of NF-κB inhibition in TQ-mediated inhibition of LPS-induced 
MCP-1/IL-6 response. Western blot analysis showed that TQ significantly suppressed NF-κB 
* * * 
* 
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activation induced by LPS as evidenced by decreased levels of phosphorylated NF-κB p65 
protein (p-NF-κB p65) (Figure. 17). In addition, TQ pretreatment inhibited the serum-induced 
phosphorylation of NF-κB p65 (Figure. 17).  
Figure. 17. TQ significantly suppresses LPS–induced activation of NF-κB pathway. 
LX2 Cells were plated in 6-well plates and serum starved overnight. Cells were pretreated with TQ 
(2µM) in serum free medium for 24h and challenged with LPS in DMEM medium containing 1% FBS 
for 10 min. Cells were harvested with lysis buffer and total protein was measured. Western blots were 
performed to detect phosphorylated-NF-κB p65 and β-actin protein levels 
2.3.4.7. TQ inhibits culture-triggered transdifferentiation of primary rat HSCs 
The aforementioned studies have demonstrated the anti-fibrotic and anti-proinflammatory 
activity of TQ on LX2, a fully transactivated human HSC cell line and fully activated primary rat 
HSCs. To examine the effect of TQ on the transactivation, freshly isolated rat HSCs were 
cultured for 7 days in the presence or absence of TQ and the mRNA expression levels of 
COL1A1, COL3A1 and α-SMA genes were determined via qRT-PCR. As shown in Figure. 18, 
there were significant increases in the mRNA expression levels of all three genes examined after 
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7 days in culture, suggesting culture-induced transactivation of rat HSCs. In contrast, TQ 
treatment significantly inhibited the culture-induced upregulation of the expression of all three 
genes, suggesting that TQ effectively inhibited the culture-triggered transactivation of primary 
HSCs.  
 
 
 
 
Figure. 18. TQ inhibited the culture-induced transdifferentiation of primary rat HSCs. 
Freshly isolated rat HSCs were cultured for one or seven days in the presence or absence of TQ and the mRNA 
expression levels of COL1A1, COL3A1, and α-SMA genes were measured by qRT-PCR. 
 
 62 
2.3.5. Discussion 
TQ is a natural product with various biological activities including hepatoprotective effects 
against hepatotoxins. A recent study has also demonstrated anti-fibrotic effect for TQ in a rat 
model of CBDL-induced liver injury (Oguz et al., 2012). However, the detailed mechanism for 
the anti-fibrotic activity of TQ remains largely unknown. It is generally regarded that the 
hepatoprotective activity of TQ plays an important role as decreased hepatocyte damage shall 
lead to reduced activation of HSC and the associated fibrogenic events. The results from the 
present study clearly demonstrated a direct inhibitory effect of TQ on HSCs, unveiling a new 
mechanism for the anti-fibrotic effect of TQ. 
Activation of HSCs represents the key initial step in the pathogenesis of liver fibrosis. 
Our data showed that TQ treatment significantly inhibited the culture-induced transactivation of 
primary rat HSCs as demonstrated by drastic inhibition of culture-triggered upregulation of 
several fibrosis-related genes including COL1A1, COL3A1, and α-SMA. In addition to blocking 
the transactivation of quiescent HSCs, TQ significantly inhibited the fibrogenic activity in fully 
activated cells: TQ-treated LX2 cells showed significantly reduced mRNA expression levels of 
COL1A1 and COL3A1 compared to vehicle-treated cells. A recent study by Bai et al. showed 
that TQ treatment reduced the LPS-induced upregulation of COL1A1 and α-SMA in T-HSC/Cl-
6 cells, an immortalized rat hepatic stellate cell line (Bai et al., 2013b). We have further shown 
that TQ could inhibit the LPS-induced proinflammatory response as demonstrated by significant 
inhibition of LPS-induced upregulation in the mRNA expression levels of MCP-1 and IL-6.  It is 
well known the cytokines and chemokines produced by activated HSCs can work on both HSCs 
and neighboring cells in autocrine and paracrine fashions, which serve to amplify the 
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proinflammatory and fibrogenic events (Bataller and Brenner, 2001). Thus, TQ can intervene at 
various steps of the complex fibrogenic processes. 
In addition to direct inhibition of fibrogenic activity in HSCs, TQ shows growth 
inhibitory effect on HSCs. It has been accepted that liver fibrosis is a reversible process, 
particularly at early stage, and elimination of activated HSCs via apoptosis plays an important 
role in the resolution of fibrotic changes (Wright et al., 2001). This has led to the development of 
a number of therapeutic strategies targeted at the induction of apoptosis of activated HSCs in 
fibrotic liver (Li et al., 2008b). The inhibitory effect of TQ on the proliferation of HSCs likely 
contributes to the overall anti-fibrotic activity of TQ in vivo, which will be further addressed in 
the future. 
The mechanism for the anti-fibrotic activity of TQ is not completely understood; however, its 
antioxidant activity likely plays an important role. It is known that the LPS/TLR4 signaling is 
critically involved in transactivation of HSCs during liver injury (Bai et al., 2013b). It has also 
been known that LPS initially promotes the production of reactive oxygen species (ROS), which 
elicits a wide spectrum of responses by activating transcription factor NF-κB through MAPKs 
and PI3K/Akt pathways (Bai et al., 2013b; Shi et al., 2013). Activation of NF-κB leads to the 
expression of not only various proinflammatory and profibrogenic factors but also antiapoptotic 
proteins such as XIAP and cellular FLIP (c-FLIPL) that might enhance the survival and 
proliferation of activated HSCs. Our data showed that activation of NF-κB by LPS in LX2 cells 
was significantly inhibited by TQ. The study by Bai et al showed that LPS treatment led to 
activation of PI3K signaling, which was significantly attenuated by TQ. These data are in 
consistent with the antioxidant activity of TQ. This is further supported by the observation that 
silymarin, a well-established antioxidant (Bindoli et al., 1977; Trappoliere et al., 2009), similarly 
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inhibited the fibrogenic activity in both human and rat HSCs.  More studies are needed to better 
understand the mechanism by which TQ exerts its anti-fibrotic and antiproliferation activity in 
HSCs. In addition to these data, we have done a side experiment to investigate other mechanisms 
that may be involved. We tested weather TQ has an impact in inhibition of serum-induced 
contraction of LX2 cells in vitro. Our preliminary results showed that TQ significantly inhibited 
LX2 contraction induced by serum using collagen lattices gel. Moreover, TQ treatment of 
culture-induced transactivation of primary rat HSCs significantly inhibited vasoactive mediators 
ET-1 gene expression, which is heavily involved in the contractile properties of activated HSCs 
(data shown in Appendix A). 
In summary, this study supports the notion that TQ has a direct anti-fibrotic and 
antiproliferation effect on HSCs. Considering its excellent safety profile and various favorable 
biological properties, TQ may represent a new type of anti-fibrotic therapy that warrants further 
study 
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2.4. PEG5K-FMOC-FTS2 MICELLE SYSTEM AS A DUAL FUNCTIONAL 
DELIVERY SYSTEM FOR TQ IN THE TREATMENT OF LIVER FIBROSIS 
2.4.1. Introduction 
Chronic liver diseases represent major health problem worldwide; the major causes include 
chronic viral hepatitis, alcohol abuse, autoimmune disease, and metabolic disorder. Long-term 
exposure to liver injury results in an abnormal wound healing response termed fibrosis 
(Friedman, 2003a; Bataller and Brenner, 2005). Injured liver cells undergo phenotypic changes, 
leading to the overproduction and deposition of ECM, which results in the replacement of 
healthy cells with scar tissue that subsequently leads to major complications, such as liver 
cirrhosis and hepatocellular carcinoma (Bataller and Brenner, 2005; Friedman and Bansal, 
2006a). There have been significant advances in the understanding of liver fibrosis pathology 
and treatment approaches. Although many potent potential anti-fibrotic drugs were discovered 
and are currently being tested in clinical trials, such as angiotensin II antagonists, interferon 
gamma, and peroxisomal proliferator activated receptor (PPAR), they often show minimal in 
vivo effect when compared to their in vitro effect (Rockey, 2008). This is likely attributed to 
lower drug concentrations reaching target sites and non-specific distribution to many organs, 
resulting in adverse drug effects. This may explain the absence of anti-fibrotic drugs in clinical 
practice.  
The recent emerging nanotherapy has introduced a promising alternative to conventional 
therapy. Nanotechnology is a growing field attracting more and more scientists over the past 
decades. Nanocarriers possess the flexibility to be engineered with wide spectrum of 
biocompatible materials in order to get the most suitable nanocarriers for the treatment purposes.  
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Numerous in vitro and in vivo studies have suggested that TQ carries significant 
therapeutic applications for many diseases, with a relatively low toxicity profile (Badary et al., 
1997; Al-Shabanah et al., 1998; Mansour et al., 2001; Zafeer et al., 2012). We have recently 
shown that TQ shows promise as a hepatoprotective and anti-fibrotic agent, particularly in 
activated HSCs, major cells for producing the ECM (Ghazwani et al., 2014). Previously, our lab 
has developed a FTS-based micellar system , a promising dual functional carrier for  delivery of 
anticancer agents such as PTX (Zhang et al., 2013b; Chen et al., 2014; Zhang et al., 2014d; 
Zhang et al., 2014e; Zhang et al., 2014f). FTS is a potent Ras antagonist, currently being 
extensively studied as new agent for cancer treatment, with the advantage of having an excellent 
safety profile (Marom et al., 1995b; Haklai et al., 1998a; Gana-Weisz et al., 2002). Also, several 
studies have reported its therapeutic activity in animal models of liver diseases. It was discovered 
that FTS exerts an anti-fibrotic effect in a rat model via inhibition of hepatic fibrogenesis 
associated with a decrease in Ras expression and reduction of HSCs proliferation and migration 
(Reif et al., 2004). Moreover, FTS accelerates the regression of experimentally induced hepatic 
cirrhosis in rats via increased collagenolytic activity, as evidenced by increased expression of 
MMP-2, MMP-9, and TIMP-2 (Reif et al., 1999).  
 This study developed a PEG5k-Fmoc-FTS2 micellar system for TQ delivery. 9-
fluorenylmethoxycarbony (Fmoc) moiety is a functional amino acid protecting group typically 
used in chemical reactions. Our lab has shown that Fmoc group is the most potent drug-
interactive moiety among numerous screened compounds (Gao et al., 2012). Fmoc can improve 
both drug-loading capacity and formulation stability (Zhang et al., 2014a; Zhang et al., 2014b; 
Zhang et al., 2014g; Zhang et al., 2015a). Here, we examine the potential of this formulation for 
the delivery of TQ in vitro using LX2, an immortalized human hepatic stellate cell line.  
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2.4.2. Materials and methods 
TQ was purchased from Sigma–Aldrich (St. Louis, MO). The purity (GC) of TQ was ≥98.5%, as 
per the manufacturer’s specification. FTS was synthesized according to published literature 
(Zhang et al., 2013a). 4-Dimethylaminopyridine (DMAP) was purchased from Calbiochem-
Novabiochem Corporation (CA, USA). Dulbecco’s phosphate-buffered saline (DPBS) was 
purchased from Lonza (MD, USA). Fetal bovine serum (FBS) and penicillin-streptomycin 
solution were from Invitrogen (NY, USA). The following chemicals were purchased from 
Sigma-Aldrich (MO, USA): succinate anhydride, diethanolamine, poly (ethylene glycol) methyl 
ether (MeO-PEG-OH, Mw = 5000 kDa), N-hydroxysuccinimide (NHS), 
dicyclohexylcarbodiimide (DCC), dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl tetrazolium bromide (MTT), and Dulbecco’s modified Eagle’s medium (DMEM).  
 
2.4.2.1 Synthesis of PEG5k-Fmoc-FTS2 conjugate 
The solution condensation method was utilized to synthesize PEG5k-Fmoc-FTS2 
conjugate. MeO-PEG-OH (1 equiv) was reacted with succinate anhydride (5 equiv) in CH2Cl2 
overnight in the presence of DMAP (5 equiv) as catalyst. The resultant PEG derivative was 
purified by precipitation in cold ether solution (twice), and extra DMAP was washed away by 
cold ethanol (twice). The resultant product (mPEG5K–COOH) was then reacted with 
tris(hydroxymethyl)aminomethane (tris), NHS (3 equiv) and DCC (3 equiv) in CH2Cl2 for 1 day. 
The product was similarly purified as previously above. P-toluenesulfonic acid (TsOH) was used 
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as a catalyst in acetone to block the two hydroxyl groups of PEG-derivatized Tris by forming 
acetonide. Then, the remaining hydroxyl group of Tris was coupled with Fmoc group through 
reaction with 9-fluorenylmethoxycarbonyl chloride (Fmoc–Cl) (2 equiv) and triethylamine (3 
equiv) in CH2Cl2 overnight. The product was purified as mentioned above, and the acetonide 
group was removed by the addition of 1% TsOH in CH2Cl2. Finally, FTS was conjugated with 
the two hydroxyl groups via reaction with DCC (4 equiv) and DMAP (0.4 equiv) as the coupling 
reagents. The reaction solution was filtered through cotton and the final product was purified by 
precipitation / washing as mentioned above.  
Figure. 19. Synthesis scheme of PEG5K-Fmoc-FTS2 conjugate 
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2.4.2.2 Preparation of PEG5k-Fmoc-FTS2 loaded TQ 
TQ (10 mM dissolved in CH2Cl2) and PEG5k-Fmoc-FTS2 (10 mM dissolved in CH2Cl2) 
were mixed with different carrier /drug ratios in glass tube as shown in table 1. The solvent was 
removed by nitrogen flow to form thin film of the mixture. Traces of solvent were removed by 
glass vacuum desiccator. Micelles were formed by hydration of film with DPBS, followed by 
gentle vortexing. 
2.4.2.3 Particles size and surface morphology measurement 
TQ-micelles concentration was kept at (Bakathir and Abbas). Particles size was measured 
via dynamic light scattering (DLS) (Zetasizer Nano ZS instrument, Malvern, Worcestershire, 
UK). Briefly, 20 μL of micelle solution was diluted with 1 mL of distilled water, and particle 
size was measured at room temperature. Size distribution and morphology was examined for 
both drug-free and TQ-loaded micelles via TEM imaging. Sample from micelles were stained 
using a copper grid with Formvar immersed in a drop of sample solution and stained with 1% 
uranyl acetate. Imaging was performed at room temperature on JEOL JEM-1011. 
2.4.2.4 Determination of drug content, entrapment efficiency (EE) and loading 
capacity (LC) 
To determine the drug loading efficiency of TQ-micelle, 10 μL was dissolved in 0.5 mL 
methanol, vortexed, and centrifuged at 12000 rpm at 4°C for 10 min. The supernatant was 
collected and drug content was quantified by high performance liquid chromatography (HPLC) 
(Alliance 2695− 2998 system). The reverse-phase Lichrospher 100 RP-18 (5 μm) column was 
used, and the mobile phase consisted of methanol/water (5:95 v/v). The flow rate was set to 0.8 
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mL/ min and the detection wavelength was 242 nm. Drug entrapment efficiency (EE) and 
loading capacity (LC) were calculated as follows: 
            EE (%) = (weight of loaded drug/weight of input drug) × 100% 
            LC (%) = [(weight of drug loaded/ (weight of SLN + drug used)] 100% 
2.4.2.5 Stability 
For stability study, freshly prepared micelle samples were stored in parafilm-sealed glass 
tubes at room temperature. Size measurements were performed daily until changes in size is 
observed.  
 
2.4.2.6 In vitro cytotoxicity study 
LX2 (2000 cells/well) were seeded in 96-well plates. Cells were incubated overnight in 
10% FBS and 1% streptomycin−penicillin. Fresh media containing TQ with indicated 
concentrations for 72 h was added to replace old media. Following, 20 µL of MTT (5 mg/mL) in 
DPBS was added to each well and further incubated for 3.5 h. Well contents were gently 
removed and DMSO was added to solubilize MTT formazan, resulting in a purple-colored 
solution. A microplate reader quantified absorbance with a wavelength of 550 nm and reference 
wavelength of 630 nm. Untreated groups were used as controls. Cell viability was calculated as 
[(ODtreat − ODblank)/(ODcontrol − ODblank) × 100%]. Drug-free micelles and free TQ in DMSO were 
examined using a similar method. 
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2.4.2.7 RNA extraction and qRT-PCR 
Total RNA was extracted with TRIzol reagent (Invitrogen). The total RNA was measured 
by NanoDrop 2000 (Thermo Scientific). Extracted RNA concentration was adjusted to be 1 µg 
per reverse transcription reaction using SuperScript III reverse transcriptase (Invitrogen). The 
primers for COL1A1, α-SMA and GAPDH were obtained from MWG Biotech. Following  
synthesis of first strand cDNA, real-time PCR was performed using SYBR Green based assays 
using an ABI Prism 7300 (Applied Biosystems, Foster City, CA). 
2.4.2.8 Statistical analysis 
In all statistical analyses, the significance level was set at a probability of P < 0.05. All 
results were reported as the mean ± standard error (SEM) unless otherwise indicated. Statistical 
analysis was performed by Student’s t test for two groups. 
2.4.3 Results 
2.4.3.1 Characterizations of micelles 
Following the successful synthesis of PEG5k-Fmoc-FTS2, determined by NMR, micelles 
were formed by film hydration as previously described. DLS size distribution indicates that drug-
free micelles and TQ-micelles had an average size of ∼30 nm each. TEM observations 
confirmed spherically-shaped micelles with a size distribution that is consistent with that seen in 
DLS (Figure 19). Moreover, an entrapment efficiency of greater than 80 % was observed for TQ-
micelles of carrier/drug ratios of (0.2:1) and (0.5:1), respectively, and the drug-loaded micelles 
were stable for more than two weeks (Table 1). 
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Figure 19. Particles size distribution of micelles.  
Drug-free micelles (A) and TQ-micelles (B) as determined by DLS. TEM images of drug-free-micelles (C) and 
TQ-micelles (D). 
2.4.3.2  MTT assay analysis 
Free TQ in DMSO exhibited a cytotoxic effect against LX2 cells in a dose-dependent 
manner. However, TQ-loaded micelles only exhibited a minimal killing effect of about 20% at 
high concentrations (100 µM) (Figure 20). No toxic effect was observed in drug-free micelles 
(data not shown).  
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Figure 20. Cytotoxicity assay of free TQ and TQ-micelles in immortalized activated human HSCs line 
(LX2). 
 
 
 
2.4.3.3 mRNA expression analysis of fibrogenic markers 
Cells treated with free TQ exhibited significant downregulation of both fibrogenic 
markers COL1A1, a major component of ECM proteins, and α-SMA – a marker for HSCs 
activation. In contrast, TQ-micelles of similar concentrations had no effect on both genes. 
However, at a higher concentration of 20 μM, micellar TQ exhibited significant inhibition of 
both COL1A1 and α-SMA genes (Figure 21).  
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Figure 21. qRT-PCR analysis of fibrotic genes expression after treatment with TQ-Micelles. 
LX2 cells were plated overnight, followed by treatment of free TQ in DMSO, drug-free micelles, and two 
concentrations of TQ-Micelles for 24 hrs. Expression of COL1A1 and α-SMA were determined by qRT-PCR. 
 
 
Table 1. Stability of TQ-micelles in different molar ratios 
 
 
2.4.4 Discussion  
This study explores the delivery of TQ into activated human HSCs (LX2) in vitro, using an 
innovative micellar system, PEG5k-Fmoc-FTS2. The system is based on a PEG conjugate with 
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two molecules of FTS together with a Fmoc group at the interfacial region. The preparation 
method of this micelle system can be easily handled and achieved in short time period. 
Previously, our lab has developed micellar delivery systems equipped with Fmoc moieties acting 
as drug interactive motifs, which has been shown to efficiently improve carrier/drug 
compatibility. The findings demonstrated that the Fmoc group can provide strong carrier/drug 
interactions, when compared to conventional micelles, by forming π-π stacking with other 
compounds carrying aromatic rings. Thus, the π-π stacking can add to the hydrophobic 
interaction between drug and carrier, allowing for increased compatibility and stability. This 
formulation readily solubilized TQ and formed spherical micelles in an aqueous solution with a 
very small size (<30 nm). TQ could be loaded into PEG5k-Fmoc-FTS2 micelles at a carrier/drug 
molar ratio as low as 0.2:1. The drug loading capacity for TQ at this ratio is 13%, with a drug 
loading efficiency of 82%. The formulation remained stable for 2 weeks at room temperature 
(Table 1). It is possible that the interaction between TQ and hydrophobic core of micelles may 
not be very high, probably because the water solubility of TQ in water is 0.87 mg/mL at 25 °C, 
which may suggest that small amount of TQ may partially dissolve in aqueous phase. This may 
explain why the loading efficiency didn’t reach 100%.  
The cytotoxicity study showed that free TQ inhibited the proliferation of LX2 cells in a 
concentration-dependent manner, while TQ formulated in PEG5k-Fmoc-FTS2 micelles did not 
show toxicity at parallel concentrations, except at a high concentration (100 μM), resulting in 
∼20% cell killing effect. Although apoptosis induction in activated HSCs is considered to be one 
of the resolution pathways in liver fibrosis therapy, the reversion of activated HSCs to a 
quiescent state is also of equivalent importance (Friedman, 2008). Interestingly, dramatic 
inhibition of COL1A1 expression was observed in the group treated with TQ-micelles. This may 
 76 
be explained by the efficient uptake of TQ-micelles by LX2 cells; and once TQ and FTS are 
released inside the cells, they work synergistically to inhibit collagen expression. These data are 
consistent with the reported anti-fibrotic effects of TQ and the effects of FTS against collagen 
expression (Reif et al., 1999; Reif et al., 2004). Also, the significant downregulation of α-SMA 
expression following TQ-micelles treatment (20 µM) suggests that TQ-micelles have a slow 
release kinetics which also may explain the minimal toxicity effect at a high dose (100 µM), as 
seen in the  cytotoxicity assay. These data suggest that LX2 cells show high tolerability to TQ 
formulated in micelles, as evidenced by their low toxicity compared to the free drug group. 
Nevertheless, the TQ formulated in micelles demonstrated significant therapeutic effect as an 
anti-fibrotic agent.  
Despite the demonstrated potential of this formulation, further studies are necessary to 
make it a better candidate for in vivo studies. Necessary studies include: the characterization of 
release kinetics, an uptake study, stability, mechanisms of action pathways, and incorporation of 
HSCs-specific ligands (e.g. mannose-6-phosphate/insulin-like growth factor receptor 
(M6P/IGFII receptor) for improved targeting. 
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2.5. CONCLUSION AND PERSPECTIVE 
Chronic liver diseases (CLD) have become an increasingly important problem worldwide. The 
prevalence of liver disease is increasing rather than decreasing, particularly when compared to 
other major causes of mortality. Current knowledge and understanding of liver disease pathology 
has advanced greatly. However, current treatment options are relatively ineffective – especially 
in advanced liver fibrosis. Therefore, there is a high demand for identifying novel approaches to 
curing liver fibrosis. Currently, herbal medicine is a popular area of research due to its promising 
therapeutic potential for liver disease. Moreover, the low cost, high availability, safety, and 
efficacy of medicinal plants make them very attractive to scientists. In addition, many herbal 
plants are widely used by various cultures or religions worldwide. The active component of 
Nigella sativa or black seed (Thymoquinone), is an example of a phytochemical with diverse 
therapeutic applications and an excellent safety profile. This study investigates TQ’s potential 
impact for the treatment of liver fibrosis. Consistent with previous reports, this study has 
indicated that TQ plays an important role in the prevention and treatment of liver fibrosis. This 
study has also shown that TQ can directly affect HSCs, the major collagen producing cells in 
liver fibrosis, by inhibition of their fibrogenic activities. Additionally, TQ significantly reduced 
the mRNA expression of the fibrosis-related genes COL1A1, COL3A1, and α-SMA. Moreover, 
TQ blocked the transactivation of primary rat HSCs in vitro. This study has also indicated that 
TQ acts via inhibiting the activity of NF- κ B induced by LPS, which may attributed to TQ’s 
antioxidant activity. However, further studies are needed to elucidate the mechanism of action 
for TQ in liver fibrosis.  
Following an investigation of TQ’s therapeutic impact on HSCs, this study further 
explored the delivery aspect of TQ into HSCs. This study developed a dual functional micellar 
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system PEG5k-Fmoc-FTS2. FTS carries therapeutic potential as an anti-fibrotic drug with an 
excellent safety profile. Also, FTS may potentially synergize with the codelivered anti-fibrotic 
drugs. TQ-micelles have very small size (<30 nm) with good stability up to two weeks at room 
temperature. This formulation didn’t exhibit cytotoxicity in LX2 cells compared to free TQ, and, 
more importantly, was able to deliver higher doses of TQ to achieve anti-fibrotic effect. 
However, further characterization studies are needed to better understand the system’s 
capabilities and limitations. Also, incorporation of HSC-specific ligands will further improve the 
potential of in vivo therapeutic outcomes. 
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3 CONCLUSION AND FUTURE DIRECTIONS 
3.4 MAJOR FINDINGS AND IMPLICATIONS 
Nanomaterial-based drug delivery systems hold promising expectations in the development of 
novel therapeutic products. The application of nanotechnology in medicine has achieved a great 
deal in solving many obstacles of conventional therapy. These obstacles include poor water 
solubility, a low therapeutic window, off-target effects, and multidrug resistance issues. The 
objective of this dissertation is to explore and develop novel nanocarriers with dual functional 
properties, rendering them capable of delivering therapeutic agents and contribute to overall 
therapy outcomes.  
In the first chapter, the development of an FTS-based SLNs formulation to deliver PTX is 
described. PTX is a potent chemotherapeutic agent that has been used for years to treat various 
human malignancies, including breast, lung, and ovarian cancer. However, its clinical application 
is greatly limited by its very low water solubility. Currently, PTX is formulated with the use of 
surfactants including Cremophore EL, which improves the drug solubility. Unfortunately, 
Cremophore EL is associated with serious side effects, such as hypersensitivity reactions. This 
study introduced a SLN formulation consisting of a solid lipid core of ethyleneglycol-di-FTS 
stabilized with PEG5k-FTS2 polymers as a dual functional delivery system for PTX. This study 
recruited FTS as part of delivery system, with potential bioactivity as an anticancer agent. FTS is 
non-toxic and a potent Ras antagonist that has been extensively studied as new anticancer agent 
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– especially in cancers with Ras mutations. Additionally, a phase-I clinical trial has demonstrated 
the safety of FTS. The SLN system in this study is characterized by small particle size (<200 
nm), which is within the size range that can penetrate through tumor leaky vasculatures. Also, 
this system exhibited an excellent stability profile. In addition, this study suggests that the PTX 
delivered by this formulation has significantly slower release kinetics with the advantage of 
avoiding burst release, when compared to Taxol formulation. Most importantly, the in vivo data 
revealed that PTX-loaded SLNs exhibit enhanced antitumor activity, as evidenced by improved 
tumor growth inhibition in mice treated with PTX-loaded SLNs when compared to both Taxol 
and control SLNs without FTS. Our results suggest that FTS-based SLNs may represent a better 
alternative to the currently used Taxol formulation for the following reasons: solving the 
solubility issue of PTX, providing potential synergy with PTX in vivo, stable formulation with 
controlled release kinetics, and targeted delivery to tumor sites. Moreover, the FTS-based SLNs 
could serve as a platform for the delivery of other antineoplastic agents with hydrophobic nature.  
In the second chapter, this study explores the possibility of delivering TQ to activated 
HSCs for treatment of liver fibrosis. The first section of the chapter is dedicated to studying the 
biological activity of TQ in activated HSCs. The second section aims to explore the delivery 
aspect of TQ to activated HSCs. 
TQ is the bioactive constituent of the Nigella sativa plant, also known as black seed. A 
large number of studies have reported TQ’s therapeutic potential for the treatment of various 
inflammatory diseases, including liver fibrosis. This study aimed to determine whether TQ could 
exert its anti-fibrotic activity directly through inhibiting the fibrogenic activity of HSCs, since 
HSCs are critical in the initiation and progression of liver fibrosis following liver injury. The 
preliminary data of this study suggest that TQ could protect against acute liver injury induced by 
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CCl4 in mice. Additionally, the gene expression of COL1A1 and α-SMA was significantly 
inhibited. In vitro analysis using human activated HSCs (LX2) cells suggest that TQ acts by 
suppressing the NF-κB pathway, leading to a reduction in expression of LPS-induced pro-
inflammatory cytokines. Moreover, TQ treatment significantly blocked the culture-induced 
transactivation of primary rat HSCs, as demonstrated by the drastic inhibition of culture-
triggered upregulation of several fibrosis-related genes. These data suggest that TQ holds great 
potential as a new drug candidate with many favorable therapeutic effects and an excellent safety 
profile for the treatment of liver fibrosis. However, future studies are still needed to fully 
understand its mechanism of action.  
The second section of chapter two outlines the development of a simple dual functional 
micellar system that is based on PEG conjugate with two FTS molecules together with a Fmoc at 
interfacial region. Aside from the antitumor activity of FTS, several studies have demonstrated 
its anti-fibrotic effect in animal models. The purpose of study is to develop a nanocarrier system 
that both efficiently delivers TQ and enhances the overall anti-fibrotic effect. Here, the novel 
micellar system was able to solubilize TQ in an aqueous solution with very small particles sizes 
(< 30 nm). The in vitro analysis, using LX2 cells, has shown that this formulation is safe and 
highly efficient in the suppression of the fibrotic genes COL1A1 and α-SMA. The incorporation 
of FTS in the micelle system may provide a potential synergistic effect with TQ, which could 
further enhance the overall anti-fibrotic activity.  
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3.5 LIMITATION AND FUTURE STUDIES 
In first chapter, although PTX-SLNs formulation has demonstrated improved performance over 
clinical formulation Taxol in terms of stability, controlled release and efficacy in vivo, there are 
several limitations that should be considered for future improvement. First, the biphasic release 
could be due to insufficient interaction between small amount of PTX and SLN’s core, which 
results in the release of ~ 25% in the first 24 h. The addition of another FTS group to solid lipid 
to become EG-FTS3 might increase the interaction strength with PTX and allow for slower 
release especially in the first few hours. Keeping in mind that these modifications will not 
significantly alter the formulation stability and efficacy. Additionally, we assumed that the 
decent antitumor activity of EG-FTS2 SLNs in vivo is due to FTS, since it possess anticancer 
activity by itself. However, in order to roll out any toxic contribution coming from EG itself, 
inclusion of another group of mice receiving only EG would strongly support our explanation if 
EG didn’t show any toxic effect by itself.  
Future studies are necessary to further enhance and strengthen FTS-based SLNs for 
cancer delivery. This may include further analysis of carrier/drug interactions to improve 
understanding of how to enhance formulation stability and drug release rate. Also, incorporation 
of a tumor-sensitive cleavable linker within the ethyleneglycol-di-FTS lipid may improve the 
controlled release of anticancer agents in tumor sites. For example, the disulfide bond is 
glutathione (GSH) responsive linker that has been extensively studied in various nanocarriers. 
Disulfide bonds showed strong stability under normal physiological conditions, with low GSH 
concentrations, and can be highly reduced in tumor environments with high concentrations of 
GSH. Consequently, this would enhance SLNs’ bioavailability in tumor tissues and avoid off-
target effects. 
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In the second chapter, the anti-fibrotic effect of TQ was studied in mice pretreated with 
TQ followed by liver injury using CCl4. The effect was further confirmed in vitro using LX2 cell 
line. However, it would be more reliable to examine TQ’s anti-fibrotic effect in an established 
liver fibrosis model. Using such a model will reflect the extent by which TQ could inhibit or 
reverse liver fibrosis. Moreover, although PEG5K-Fmoc-FTS2 shows a great potential as 
delivery system for TQ, the entrapment efficiency remains limited (~ 80%). This may be 
attributed to insufficient hydrophobic interaction between TQ and the carrier. Considering the 
solubility of TQ in water, liposomes might be another delivery system candidate for TQ because 
of its capability to load both hydrophilic and hydrophobic agents, assuming that TQ might have 
partial water solubility.  
Additional studies are needed to further improve the micellar delivery system for the 
treatment of liver fibrosis in the future. One direction could include the incorporation of HSC-
specific ligands in the micelle surface to allow for active targeting of activated HSCs, and 
enhance their cellular uptake while minimizing unwanted off-target effects. Moreover, studying 
the mechanism of interaction between drug and carrier is of great importance to elucidating new 
perspectives on the improvement of delivery system stability and compatibility with delivered 
drugs. 
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APPENDIX A 
Figure 22. TQ significantly inhibited LX2 serum-induced contraction. 
Collagen gel lattices were prepared, and then LX2 were plated over the lattices for overnight. Cells were 
pretreated with TQ in 1% FBS for 24 hrs, followed by addition of 20% FBS and collagen lattices edges 
were released from wells.  24 hrs later, pictures were taken and quantified. 
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Figure 23. TQ treatment during transactivation process of cultured-activated rat HSCs significantly 
inhibited ET-1 expression. 
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APPENDIX B 
Table 2. Sequences of real-time PCR primers 
Gene Forward primer Reverse primer 
Homo sapiens COL 
1A1 
AAGAGGAAGGCCAAGTCGA
G 
CACACGTCTCGGTCATGGT
A 
Homo sapiens COL 
3A1 
CTGGTCCAAAGGGTGACAAG GCCAGGAGGACCAATAGG
A 
Homo sapiens α-SMA AGCCAAGCACTGTCAGGAAT CCAGAGCCATTGTCACACA
C 
Homo sapiens 
GAPDH 
ACCTTCCAGCAGATGTGGAT AGTCATAGTCCGCCTAGAA
GC 
Homo sapiens MCP-1 TAGCAGCCACCTTCATTCCC CTGCACTGAGATCTTCCTA
TTGG 
Homo sapiens IL-6 CCAGAGCTGTGCAGATGAGT GCATTTGTGGTTGGGTCAG
G 
Homo sapiens ET-1 TCTCTCTGCTGTTTGTGGCT GGACTGGGAGTGGGTTTCT
C 
Mus musculus 
COL1A1 
GTTCAGCTTTGTGGACCTCC TTTCCACGTCTCACCATTG
G 
Mus musculus α-SMA GACACCACCCACCCAGAG CAGAGCCATTGTCGCACAC 
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